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Abstract 
 
 Hemoglobin-based oxygen carriers provide a promising future as an alternative to 
human blood transfusions. Hemoglobin-based oxygen carriers, HBOCs, provide a low-
cost, easy to maintain, and safe solution. They require no refrigeration and are universally 
compatible, and the required transfusion volume is less than that of a normal transfusion. 
HBOCs have been known to have adverse side effects such as renal toxicity, 
gastrointestinal dismotility, and hypertension. Many of these problems stem from the lack 
of a membrane, which protects the hemoglobin from dissociating and extravasating into 
the blood vessel wall. Extracellular hemoglobin, like that found in HBOCs, has a greater 
affinity for nitric oxide, NO, than oxygen due to the lack of a protective membrane like 
that of a red blood cell. This NO scavenging effect has been used to explain the increase 
in mean arterial pressure, MAP, as well as any other smooth muscle dysfunction. NO has 
been accepted as the endothelial derived relaxing factor which serves to dilate or 
maintain the vascular tone of the arterioles. It is theorized that the drop in NO due to 
scavenging by hemoglobin causes an increase in MAP. In this study, using the mesentery 
of rats as a model to observe the microcirculation, various doses of HBOC 201, HBOC 
205 (MW 400), and HBOC 205 (MW 600) were infused into the rats. Measurements of 
MAP and arteriolar diameter were taken in response to increasing doses of each HBOC to 
establish a dose-response relationship. Chemicals such as sodium nitrite, NaNO2, and Nw-
Nitro-L-arginine methyl ester hydrochloride, L-NAME, a NOS inhibitor, were used to 
chemically alter the levels of NO. The purpose was to see if modifying the levels of NO 
could alter the changes in MAP due to the HBOCs. MAP rose in response to the 
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increasing doses of HBOCs, but the arterioles failed to show any vasomotor responses. 
NaNO2 showed an ability to reduce the increase in MAP as a result of the HBOC, but 
again had no affect on arteriolar diameter. L-NAME was able to reproduce changes in 
MAP similar to that of the HBOCs, but again had no effect on diameter. The results 
support the theory of NO scavenging by the HBOC leading to an increase in MAP. The 
lack of activity in arterioles indicates that NO may not be a major factor in controlling 
vascular tone in this tissue. The results support that HBOC’s side effects are a result of 
NO scavenging, but further work is needed to better understand vasoactivity in the 
mesentery. 
 
 
  
1
 
Introduction 
 
The Cardiovascular System 
 
Circulation 
 
 The circulatory system of our body functions to provide an adequate flow of 
blood for the entire body. It centers around the heart which works as a pump to move 
blood from the veins into the arteries. Blood enters the right atrium of the heart, is 
pumped to the right ventricle then goes to the lung via the pulmonary artery. In the lung, 
oxygen is taken up and carbon dioxide is expelled. From the lung, the blood moves into 
the left atrium from the pulmonary veins and then flows into the left ventricle. The left 
ventricle forcefully pumps the blood into the aorta from which the blood is distributed 
throughout the body via the vast network of arteries and capillaries. Blood delivers 
oxygen to the various organs of the body. The deoxygenated blood is returned to the heart 
by the veins. All the veins of the body feed into two major veins, the superior and inferior 
vena cava. The superior vena cava receives blood from the upper portion of the body and 
the inferior vena cava receives blood from the lower portion of the body. Both veins feed 
the deoxygenated blood to the right atrium of the heart. As an overview, the heart pumps 
oxygenated blood into the arteries, which delivers oxygen to the body by the capillaries 
and is returned to the heart by the veins. 
The microcirculation is the location in the circulatory system where oxygen 
exchange takes place. As the arteries decrease in size they become arterioles. The 
arterioles further decrease in size becoming capillaries. The arterioles are responsible for 
a significant portion of the vascular resistance. This is achieved because of the cellular 
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make up of the walls of the arterioles. The walls are mostly made up of smooth muscle 
cells, which are regulated by the sympathetic nervous system and local or circulating 
vasoactive factors, and together the arterioles act to regulate the blood flow. The 
arterioles feed into the smaller capillaries, which are comprised of a thin single layer of 
endothelial cells with a lumen only wide enough for the passage of red blood cells in 
single file. The exchange of water and small solutes occurs in the capillaries. The 
capillaries then widen into venules, which further widen into veins that return to the 
heart. 
Blood Composition 
 
 Blood makes up roughly 7% of the human body weight and is more of a 
heterogeneous than homogeneous solution. It is comprised of 55% plasma, an aqueous 
solution made up mainly of water, blood plasma proteins, and inorganic electrolytes. 
Plasma is able to transport gases, lipids, carbohydrates, hormones, waste, clotting factors, 
and other nutrients the body may need. The remaining 45% of the blood is composed of 
the following corpuscles: platelets (150,000-400,000), white blood cells (7,000-12,000), 
and red blood cells (4.5-5.5 million per cubic millimeter) (Nucci and Abuchowski 1998). 
Platelets act to help blood clot, white blood cells, or leukocytes, are part of the immune 
system acting to destroy pathogens, and red blood cells, or erythrocytes, contain the 
blood’s hemoglobin that transports oxygen. 
Oxygen 
Cellular Requirements for Oxygen 
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 All cells in the body need a continuous supply of oxygen to produce the necessary 
energy to carry out day to day functions. Adenosine triphosphate (ATP) is used by cells 
as a source of energy drawing from the high energy bonds of ATP. ATP can be produced 
both by anaerobic and aerobic metabolic pathways. Anaerobic pathways do not require 
the oxygen that aerobic pathways require. In addition to needing no oxygen, less energy 
is created by the process of glycolysis, which also produces by-products that can be 
harmful to the body, such as lactic acid. The aerobic pathway uses oxygen and is the 
much more efficient pathway of the two. Its by-products are water and carbon dioxide, 
which can easily be eliminated by the body. Of the two, the aerobic pathway is the much 
more efficient of the two and is why cellular respiration has such a high demand for 
oxygen. 
Oxygen Transport 
 
 Oxygen can be transported in the blood by one of two ways: dissolved in the 
plasma or bound to hemoglobin. Dissolved oxygen plays a very small part in oxygen 
transport, since only about 2% of the total oxygen is carried in this way and is an 
inadequate supply of oxygen for the body. Hemoglobin is the other method of delivery 
that makes up for the other 98% of oxygen transport. Oxygen is able to bind reversibly to 
hemoglobin allowing it to bind oxygen when PO2 is high and release it when PO2 is low. 
Hemoglobin is transported around the body and is found encapsulated in red blood cells. 
 Oxygen is able to diffuse through the membrane of the red blood cell and bind to 
hemoglobin causing a conformational change in the hemoglobin. Hemoglobin has four 
sites available for oxygen binding and the conformational change causes the three other 
binding sites to cooperatively bind other oxygen. This results in a progressive increase in 
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affinity as oxygen molecules are bound one by one to the hemoglobin. This also applies 
in a reverse manner, as oxygen is released from its binding sites on hemoglobin and, the 
affinity for oxygen decreases. The cooperative binding of oxygen to hemoglobin is 
manifested in a sigmoidal-shaped binding curve. The curve can be shifted by various 
local factors such as PCO2, pH, and temperature, which ultimately affect the rate of 
disassociation of oxygen from hemoglobin. 
Hemoglobin 
 
 Hemoglobin is the molecule found in red blood cells that is responsible for the 
transport of oxygen. Each human red blood cell contains roughly 300 million molecules 
of tetrameric hemoglobin. The red blood cell membrane encapsulates and protects the 
hemoglobin from dissociation and gives the hemoglobin a life span of 120 days, which is 
usually the life span of the red blood cell itself (Winslow 2000). Hemoglobin is a 64 kDa 
tetrameric protein that consists of two α chains and two β chains. Each of the four 
polypeptides of the hemoglobin molecule contains a single heme group which is a single 
iron atom surrounded by a porphyrin structure. The heme groups are the sites of oxygen 
binding where a single oxygen molecule can reversibly bind to a single heme group, 
allowing four oxygen molecules to bind to a single hemoglobin molecule (Kim and 
Greenburg 2004). The average percent hematocrit in an adult human is 45% with a 
normal blood concentration of hemoglobin at 15 g/100 ml. Each hemoglobin molecule is 
capable of carrying 1.34 ml O2/g Hb which means that the total oxygen carrying capacity 
of human blood is 20ml O2/dl (Berne and Levy 1998). 
 
  
5
 
Nitric Oxide 
 
Physiological Effects 
 
 Nitric Oxide, NO, is a small, diatomic, free radical gas molecule that is lipophilic, 
allowing it to pass freely through cellular membranes and other tissues. NO does contain 
a free electron making it very reactive and unstable. Unlike most free radicals, NO has a 
low level of reactivity which allows it to penetrate into tissues much further without 
reacting than a faster reacting free radical (Lane 2002). NO itself has a wide array of 
physiological activities. Several actions include promoting and suppressing apoptosis; 
acting as both an oxidant and antioxidant; emptying of the stomach; control of blood 
flow; release of hormones and neurotransmitters; learning and memory; pain sensation; 
and protection of cells from cellular parasites. This is achieved because of the variety of 
NO species and the available protein targets. Nitrogen oxide is able to react with oxygen 
species, other free radicals, transition metals, thiols, molecular oxygen, and redox 
reactions to create new products that only further nitric oxide’s ability to exert its effects 
on a larger array of targets. Several sites in which nitric oxide plays a physiological role 
include the brain, lungs, kidneys, GI tract, and blood flow. NO is able to bind to 
cytochrome c oxidase, which is located in the mitochondria. This molecule is part of the 
final pathway, the electron transport chain, for cellular respiration and normally uses 
oxygen as the electron acceptor; however NO will bind to this molecule preventing 
oxygen from receiving the electron. This causes a disruption in cellular respiration and 
decrease in oxygen consumption due to NO’s ability to disrupt the electron transport 
chain in the mitochondria. 
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Vasoactivity 
 
Vasoactivity is controlled by the sympathetic inputs to the arterioles and in 
tandem, local and circulating factors. One such factor that controls vasodilation is known 
as Endothelial Derived Relaxing Factor, EDRF. EDRF has been shown to affect the 
endothelium in arterioles by causing the smooth muscle to relax. It has been shown that 
without the endothelium, the ability of the arteriole to dilate is severely reduced (Iwatani 
2008). Nitric oxide (NO) is the most likely molecular candidate for EDRF. It has been 
shown the EDRF activity and NO levels parallel each other leading to the conclusion that 
NO is in fact EDRF and a vasodilator (Palmer 1987). NO acts by activating soluble 
guanylate cyclase, sGC, that produces cGMP from GTP. The rise in cGMP then causes a 
decrease in intracellular calcium . The drop in intracellular calcium causes a 
dephosphorylation of myosin in the smooth muscle causing relaxation of the smooth 
muscle and overall vasodilation (Lane 2002). NO is also able to react with hemoglobin 
after which it becomes inactive (Lane 2002). 
Nitric Oxide Synthase 
 
 Nitric oxide is produced by nitric oxide synthase, NOS, which has three isoforms:  
nNOS, iNOS, and eNOS. Each NOS is found in a different area of the body with small 
differences among the three. Neuronal NOS, nNOS, is found in the brain and skeletal 
muscle and constitutively produces low levels of NO; endothelial NOS, eNOS, is found 
in the endothelium and cardiac muscle and constitutively produces low levels of NO; and 
inducible NOS, iNOS, is found in macrophages and possibly all nucleated cells and can 
be induced to produce high levels of NO. All three follow a similar pathway of nitrogen 
oxide production. L-arginine and oxygen are reacted together in the presence of NADPH, 
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which acts as an electron donor, to produce L-citrulline and nitric oxide. The regulation 
of NOS is all calcium-dependent except for iNOS (Lane 2002). Nω-Nitro-L-arginine 
methyl ester hydrochloride (L-NAME) is a non-selective inhibitor of NOS enzyme 
activity. L-NAME has been used as a potent vasoconstrictor because of its ability to 
reduce the action of NOS and drastically reduce the levels of NO produced by the 
endothelium. 
Hemoglobin-Based Oxygen Carriers 
History 
 
 Hemoglobin-based oxygen carriers have always been an attractive alternative to 
blood transfusions. Even though the current blood supply provides a source of relatively 
safe blood, screening is not always perfect and the occasional transmission of disease or 
viruses does occur. Transfusions always run the risk of unfavorable host reactions, 
postoperative infectious complications, and other various side effects. Human blood also 
has a relatively short shelf life of 42 days and requires refrigeration to remain safe for 
use. When human blood is required, the use of allogenic blood requires that the donor 
blood be matched to the recipient (Gould 1996, Spahn 1994). The source of allogenic 
testing and limited shelf life comes from the actual membrane of the red blood cell 
(RBC). Each RBC contains the durable hemoglobin protein, which is actually able to 
survive outside for the RBC membrane (Gould 1996). 
 HBOCs have proven to be very effective replacements to human blood 
transfusions. HBOCs do not require refrigeration, have a much longer shelf life, and are 
universally compatible. Patients who received HBOCs required a smaller transfusion 
volume due to HBOCs’ increased oxygen capacity. HBOCs have been shown to improve 
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wound healing, enhance hepatic cell proliferation, and decrease splanchnic bacterial 
translocation when compared to human blood transfusions (Spahn 2001). 
 An unmodified hemoglobin solution is derived from outdated blood. There has 
been no evidence that the source of the hemoglobin is of any consequence. The RBCs are 
rinsed with a pyrogen-free water which causes the cells to undergo lysis. After several 
filtration steps, pure hemoglobin is extracted from the RBC membrane debris. Since the 
antigens of the RBC are found on the stroma, or membrane of the RBC, the new solution 
is universally compatible and is referred to as stroma free hemoglobin (SFH). When 
preparing solutions, colloid osmotic pressure is adjusted to ensure that the concentration 
is isooncotic and safe for clinical use. SFH has been shown to be able to support life in 
primates that lack RBCs (Spahn 2001, Gould 1996). 
Side Effects of HBOCs 
 
 It has been shown that as useful as unmodified tetrameric hemoglobin is; it does 
have some unwanted side effects. The tetrameric hemoglobin molecule has a tendency to 
dissociate when outside of the RBC. This leads to the formation of dimers that causes 
renal complications and reduction in function; oxidative stress; and unwanted rapid 
clearance of the unmodified tetrameric hemoglobin. In addition there seems to be an 
interference with the smooth muscle that causes hypertensive and gastrointestinal side 
effects. It is believed that the hypertensive effects derive from the fact that hemoglobin is 
a NO sink leading to vasoconstriction (Spahn 2001, Gould 1996, Olson 2004). Baxter 
Hemoglobin Therapeutics was able to produce an HBOC known as HemAssist, which 
made it to Phase III clinical trials, but began exhibiting adverse side effects. HemAssist 
was a diaspirin cross-linked human hemoglobin, DCLHb. By 1998, Baxter stopped 
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production due to reports that extracellular hemoglobin was toxic and unsuitable as a 
blood substitute. One of the serious side effects noted was a significant spike in blood 
pressure after administration of the DCLHb (Olson 2004). 
 There are two major theories as to the cause of the vasoactivity of HBOCs. The 
most widely accepted theory is related to the ability of free tetramers to act as NO 
scavengers. When the hemoglobin tetramer is free from the RBC, it is able to extravasate 
into and across the vessel wall where it is able to scavenge NO. In normal human blood, 
the hemoglobin is encased in the RBC preventing the hemoglobin tetramer from moving 
into the endothelium. The sudden drop in NO due to scavenging causes a drastic 
reduction in vasodilator tone and results in vasoconstiction. The ability of hemoglobin to 
extravasate comes from the lack of the RBC membrane and the ability of the tetramer to 
move into the endothelium. Once in the endothelium, hemoglobin’s affinity for NO is 
8,000 times that of oxygen. The alternative theory relies on HBOC’s increased ability to 
transport oxygen to the smooth muscle of the vascular wall. The idea is that the 
vasoconstriction comes from an autoregulatory response due to the increased oxygen 
delivery to the smooth muscle. So in theory, one might be able to alter the effects of 
vasoconstriction by altering the P50, or the affinity of the hemoglobin for oxygen. One 
such study showed that differences in P50 among various HBOCs did not produce a 
difference in total peripheral resistance (TPR) or mean arterial pressure (MAP) (Olson 
2004). The NO scavenging theory is currently the most widely accepted and steps have 
been taken to try to curb this unwanted side effect by trying to physically alter the 
hemoglobin molecule to limit its interaction with NO. 
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Alternatives to HBOCs 
 
 Perflourocarbons, PFCs, are derived from hydrocarbons with all of the hydrogen 
atoms replaced with fluorine atoms. A high gas solubility, low viscosity, and biological 
inertness characterize this synthetic compound. PFCs are emulsified in a plasma-like 
aqueous fluid such as albumin to prevent the formation of embolisms and infarctions. 
PFCs are capable of dissolving large amounts of gases, mainly oxygen and carbon 
dioxide. A PFC can dissolve 20-30 times the amount of oxygen as can plasma or water. 
This allows them to be able to deliver an amount of oxygen that is proportional to the 
PO2 of the blood. 
Modification of HBOCs 
 
 A great deal of effort has been put into minimizing the side effects associated with 
earlier HBOCs. It is now believed that many of the toxicities come from the free 
tetramers of hemoglobin and their dissociation into dimers. Several theories have been 
proposed to help prevent these unwanted side effects by altering the hemoglobin protein 
itself. Several approaches try to tether the hemoglobin together or to other 
macromolecules. One such approach has been to create a conjugated tetramer that is a 
tetramer bound to a macromolecule such as polyethlyne glycol. This prevents 
extravasation across the microvessels by increasing the overall size of the hemoglobin 
molecule. Cross-linked tetramers are another approach by which the tetramer is bound 
together to prevent dissociation into dimers. Polymerization is another method by which 
tetramers are linked to each other using glutaraldehyde, forming a polymer of tetramers. 
The final method is encapsulation within a lipid membrane or liposome which tries to 
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mimic the natural membrane which surrounds the hemoglobin in a RBC. Of the four 
described approaches, the polymers and encapsulation proved to be the most effective in 
preventing extravasation (Spahn 1994, Olson 2004). The polymerized tetramer is unable 
to pass through the vessel wall and therefore remains in the lumen allowing NO to exert 
its normal effects. It has been shown that the increase in MAP is inversely proportional to 
the size of the hemoglobin “particle,” indicating that the increased size decreases the 
likelihood of extravasation (Olson 2004). 
 
Purpose of the Study 
 
 The purpose of this study was to further investigate the NO scavenging hypothesis 
of the pressor response to HBOC infusion. The goal of the study was to investigate 
whether or not NO scavenging was responsible for the vasoconstriction found when using 
HBOCs. For each study, the mean arterial pressure and diameters of three different sizes 
of arterioles from the mesentery were monitored and recorded. The animal model for the 
studies was the male Sprague-Dawley rat. Three different HBOCs were studied by 
administering increasing doses to establish a dose response relationship to observe the 
increase in MAP and arteriolar vasoconstriction in the mesentery. In addition, sodium 
nitrite was administered to chemically alter the levels of NO and observe whether MAP 
and arteriolar diameter would return to baseline with increasing levels of sodium nitrite 
following a single dose of HBOC. Finally, a single dose of L-NAME, a NOS inhibitor, 
was administered to mimic a dose of HBOC, followed by increasing doses of sodium 
nitrite. The goal of the last study was to see if L-NAME, which decreases NO production 
via NOS inhibition, would mimic similar effects as that of a single dose of HBOC and 
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would return to MAP and arteriolar diameter to baseline with increasing doses of sodium 
nitrite like the HBOC. It was anticipated that an increase in MAP and a decrease in 
arteriolar diameter would be observed with increasing doses of HBOC. The increasing 
sodium nitrite should replace the scavenged NO and return MAP and diameter back to 
baseline. If the HBOC acted by scavenging NO, then L-NAME should produce similar 
effects to that of the HBOC. The actual results showed the expected increase in MAP 
with increasing doses of HBOC, and a return to baseline following increasing doses of 
sodium nitrite. The L-NAME produced results with increases in MAP similar to that of 
the HBOC. These results indicated that NO scavenging was a plausible theory due to the 
response of MAP to HBOCs. The vessel diameters, however, showed little to no response 
throughout the studies and indicated that NO is not a major player in the vasoactivity of 
the arterioles of the mesentery. 
Methods and Materials 
 
Animal Preparation: 
 
For the study, 36 male Sprague-Dawley rats with an average weight of about 300 
± 5 (SE) grams were used. They were all housed in pairs with access to food and water 
and put in a temperature- and light-controlled environment with 12 hours of light and 12 
hours of dark. 
The animals were initially anesthetized with a mixture of ketaset and 
acepromazine (75mg/kg of ketamine and 2.5mg/kg of acepromoazine, Henry Schein, 
Melville, NY) with approximately 0.1ml per 100g of body weight; additional doses were 
given as needed at increments of 0.1ml or 0.05ml. The site of intraperitoneal injection 
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was the underside of the animal with care to avoid piercing any of the major organs. The 
animal’s neck, ventral thigh region, and ventral stomach regions were shaved using 
electric shears. 
 
Surgical Procedures: 
 
The animal was placed in the supine position on a heated pad which maintained a 
temperature of 37 °C. The toe pinch reflex and the eye reflex were used to ensure the fact 
that the animal was completely anesthetized before the surgery began. Prior to the 
surgery, three syringes full of heparinized saline were prepared for the cannulation. The 
initial incision was at the ventral side of the inner thigh. The right femoral vein and artery 
were located and cannulated with PE-90 tubing with a PE-10 tip and a syringe of 
heparinized saline. The cannula was secured with 5-0 braided surgical silk. The femoral 
vein was used to infuse Alfaxan (Alfazalon 10mg/ml, Abbeyvet Export LTD, North 
Yorkshire, England) to maintain adequate anesthesia during the procedure. The femoral 
artery was use to measure the mean arterial pressure and take blood samples for 
hematocrit, arterial blood gas measurements(ABL 705, Radiometer America Inc., 
Westlake, OH), and hemoglobin measurements (Radiometer OSM3, Radiometer, 
Crawley, West Sussex, UK). Another incision was made on the ventral side of the neck. 
Then PE-240 tubing was placed in the trachea of the rat and tied in place with 5-0 
surgical silk. With the same incision, the left jugular vein was located and cannulated 
with PE-10 tubing and a syringe of heparinized saline that was used to infuse solutions. 
The incisions were closed using Super Glue. 
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Mesentery Preparation 
 
A 1.5 inch incision was made on the ventral side of the rat from the sternum 
down. The skin was separated from the abdominal wall. Another incision was made into 
abdominal muscle and cauterized (Gemini RS-300, Roboz Surgical Instrument Co., 
Rockville, MD) to prevent any bleeding that might bleed onto the preparation. The 
animal was then placed on a thermostatic platform. The platform was custom-made to 
allow the animal to maintain a constant temperature via a heated plate. The animal was 
placed on its side with the incision of the abdomen in line with a raised clear circular 
pedestal. A loop of the mesentery was gently placed over the viewing window on the 
platform. The criterion for an acceptable loop of the mesentery was clearly visible 
arteries located in the membrane of the mesentery. It was kept moist using PBS and was 
then wrapped with Saran wrap to keep the mesentery from drying out and to prevent gas 
exchange with the atmosphere. The platform was then secured to the stage of an imaging 
microscope. During a 30-minute acclimation period, blood samples were taken from the 
animal, and meanwhile three arterioles of different sizes were located. 
 
Properties and Preparation of HBOC’s 
 
Three types of HBOC’s, HBOC 201, HBOC 205 (MW400), and HBOC 205 (MW 
600), were used for similar experiments. All three were obtained from Biopure 
Corporation and are derived from purified bovine hemoglobin that is crosslinked by a 
reaction with glutaraldehyde in modified Ringer’s lactate to form hemoglobin polymers. 
HBOC’s are stable when stored at room temperature or at a refrigerated temperature of 2-
30 °C for up to 36 months. 
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HBOC 201 Infusions 
 
 HBOC 201 was prepared at 5 different concentrations, 0.01 µM, 0.1 µM, 1 µM, 
10 µM, and 100 µM. The desired concentrations of HBOC were calculated by taking into 
account both the altered plasma volume produced by the serial infusions and the current 
plasma concentration of HBOC 201 produced by previous injections (see checklist for 
equations used). For each of the first four infusions, the volume injected was 0.1ml. 
Dilutions of the stock HBOC 201 solution, 12.4 g/dL, were calculated and prepared. 
Normal saline was used to perform any of the necessary dilutions. For the final injection, 
100 µM, the stock solution was used without any of the previous dilutions. 
HBOC 205 (MW 400) 
 
HBOC 205 (MW 400) was prepared at 4 different concentrations, 1µ M, 10 µM, 
100 µM, and 300 µM. The desired concentrations of HBOC were calculated by taking 
into account both the altered plasma volume produced by the serial infusions and the 
current plasma concentration of HBOC 205 (MW 400) produced by previous injections 
(see checklist for equations used). For the first two infusions, the volume injected was 0.1 
ml. Dilutions of the stock HBOC 205(MW 400) solution, 13.2 g/dL, were calculated and 
prepared. Normal saline was used to perform any of the necessary dilutions. For the final 
two injections, 100 µM and 300 µM, the stock solution was used without any of the 
previous dilutions. 
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HBOC 205 (MW 600) 
 
HBOC 205 (MW 600) was prepared at 3 different concentrations, 10 µM, 100 
µM, and 300 µM. The desired concentrations of HBOC were calculated by taking into 
account both the altered plasma volume produced by the serial infusions and the current 
plasma concentration of HBOC 205 (MW 600) produced by previous injections (see 
checklist for equations used). For the first infusion, the volume injected was 0.1 ml. 
Dilutions of the stock HBOC 205 (MW 600) solution, 13 g/dL, were calculated and 
prepared. Normal saline was used to perform any of the necessary dilutions. For the other 
two injections, 100 µM and 300 µM, the stock solution was used without any of the 
previous dilutions. 
 
Solutions Prepared 
Normal Saline 
 
Normal saline was use create the solutions used for the infusions. The solution 
was prepared using 9.08g of NaCl in 1L of deionized water. 
 
Heparinized Saline 
 
 Heparinized saline was used to prevent clotting in the tubing of the cannulas or 
near the sites of cannulations in the vein or artery. The solution was prepared using 10 ml 
of 1000 u/ml heparin in 1L of normal saline. 
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Sodium Nitrite 
 
 Sodium nitrite in the body is able to deliver extra nitric oxide to the vascular 
smooth muscle. It acts to reduce hypertension via vasodilation of the blood vessels. 
 
L-NAME 
 
 Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) is a non-selective 
inhibitor of NOS enzyme activity. A solution was made by dissolving 300 mg of L-
NAME (Sigma, St. Louis, MO) in 10 ml of deionized water to arrive at a final 
concentration of 30 mg/ml. In the L-NAME portion of the experiments, a 5 mg/kg dose 
was given intravenously. The amount given was directly proportional to the body weight 
of the animal. 
 
Imaging Microscope and Software 
 
Microscopic measurements were made using an Axioplan-2 microscope (Zeiss, 
Thornwood, NY) equipped with Achroplan objectives. The microscope was connected to 
a CCD camera (Cool Snap cf, Roper Scientific, Tucson, AZ) and a computer (Dell 
Dimension 8250, Dell), which was used for acquiring images of the microcirculation. 
The automatic features of the microscope were controlled with IP Lab software (version 
3.6, Scanalytics, VA). IP Lab controlled image acquisition, and the diameter 
measurements were made directly over the image generated. A 100-watt halogen lamp 
was used to transilluminate the muscle preparation. Objective 4X/NA = 0.10 (Achroplan, 
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Zeiss, Thornwood, NY) was used for observing and identifying the three arterioles that 
were to be measured. The same objective was used to measure the large and medium 
arterioles. The objective 20X/NA = 0.45 was used to measure the smallest arteriole. An 
initial and baseline image was taken before any part of the experiment began, and 
additional images were taken at the time of the infusion, 5 minutes after, and 10 minutes 
after. 
 
Data Acquisition 
 
Measurement of Mean Arterial Pressure 
 
The cannula in the femoral artery was used to measure the mean arterial pressure 
of the animal throughout the procedure. The cannula was connected to the CyQ 103/301 
acquisition and display system (CyberSense Inc., Nicholasville, KY). The system gave a 
continuous reading of the MAP that was recorded at regular intervals. For all of the 
experiments, there was an initial reading recorded when the animals was first put on the 
microscope platform and another baseline reading right before the first infusion that was 
preceded by the 30-minute acclimation period. From then on, a measurement was taken 
at the time of the infusion, 1 minute after the infusion, 5 minutes after the infusion, and 
10 minutes after the infusion. This process was repeated for all infusions for all of the 
experiments. The transducer was placed at the level of the animal’s heart to give an 
accurate blood pressure reading. The MAP was used to monitor the animal’s systemic 
response HBOC infusion and to give the time course of MAP, as well as the dose 
response relationship between the infusions and the average change in MAP. 
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Measurement of Arteriolar Diameter 
 
 The three arterioles were chosen based on the clarity of the image. The ideal sizes 
for the three vessels were about 300 µm for the largest, 200 µm for the intermediate, and 
40 µm for the smallest. Clarity and ease of measurement were the primary criteria when 
selecting the vessels to be measured. The transillumination images were captured via the 
camera and saved to IP Lab for later viewing and diameter measurements. The images 
were captured 1 minute after the infusion, 5 minutes after the infusion, and 10 minutes 
after the infusion. The measurements were later displayed to give the time course of 
diameter of the three arterioles, as well as a dose response relationship between the 
infusions and average change in arteriolar diameter. 
 
Experimental Protocol 
Human Serum Albumin 
 
 Human serum albumin (HSA) was used as a volume control prior to the initial 
experiments with HBOC’s. This was to establish the response in a control group that was 
injected with a solution of similar osmolarity and concentration as the HBOC infusions. 
 
HBOC 
 
For the HBOC portion of the protocol, three series of experiments were done with 
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HBOC 201, HBOC 205 (MW400) and HBOC 205 (MW600). For all three, similar 
protocols were followed. The goal was to establish a dose-response relationship between 
MAP and diameter of the three arterioles as a function of HBOC concentrations. After 
the animal was placed on the stage of the microscope and three arterioles were located 
and baseline MAP measurements were taken, calculations and dilutions were preformed 
to prepare the necessary HBOC concentrations. HBOC infusions were prepared using the 
stock solution of HBOC 201, 205 (MW400), and 205(600). For HBOC-201 (n=6), five 
different plasma concentrations were prepared, 0.01, 0.1, 1.0, 10.0, and 100.0 µM. For 
HBOC-205 (MW 400) (n=6), four different plasma concentrations were prepared, 1.0, 
10.0, 100.0, and 300.0 µM. For HBOC-205 (MW 600) (n=6), three different plasma 
concentrations were prepared, 10.0, 100.0, and 300.0 µM. After the 30-minute 
acclimation period, and measurements of baseline MAP and diameters were made, the 
infusion was administered. Each dose was separated by a 15-minute interval with 
measurements taken in between. MAP measurements were taken immediately after the 
infusion, one minute later, five minutes later, and 10 minutes later. Diameter 
measurements were taken one minute later, five minutes later, and 10 minutes later. 
Sodium Nitrite Controls 
 
 A control group, n=2, was used to establish a baseline response for NaNO2. The 
rats were given increasing doses of NaNO2, 10 µM, 100 µM, 1 mM, and 3 mM. Doses 
were given at fifteen minute intervals with measurements taken in between. MAP was 
taken at the time of the infusion, one minute after, five minutes after, and 10 minutes 
after. Diameter was taken one minute after, five minutes after, and 10 minutes after the 
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infusion. This was repeated for all doses. 
NaNO2 and HBOC Time Controls 
 
A time control was taken to observe the length of time the HBOC and NaNO2 
were still effective. For the HBOC time control (n=2), a single dose of 100 µM HBOC-
201 was infused. MAP was taken at the time of the infusion, one minute after, and every 
five minutes after until a return to baseline was observed. Diameter measurements were 
made one minute after the infusion and every 5 minutes thereafter until a return to 
baseline was observed. For the sodium nitrite control (n=1), the animal was give a single 
does of 100 µM HBOC-201 followed by an injection of 100 µM NaNO2. MAP was 
measured at the time of the injection, 1 minute after, and every five minutes until a 
decrease in the NaNO2 effect was observed. Diameters were measured 1 minute after the 
infusion and every five minutes until the effects of the NaNO2 began to decrease. Then a 
1 mM infusion was given and measured by the same protocol as the 100 µM injection.  
HBOC and NaNO2 
 
For this portion of the study (n=6), the animal was given an initial dose of 100 
µM HBOC-201 followed by increasing doses of NaNO2: 10 µM, 100 µM, 1 mM, and 3 
mM. Doses were given at 15 minute intervals with measurements taken in between. MAP 
was taken at the time of the infusion and every five minutes there after. Diameter was 
taken one minute after the infusion and every 5 minutes thereafter. 
Simultaneous HBOC and NaNO2 
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For this portion of the study (n=2), a dose of 100 µM HBOC 201 was given, 
followed immediately by a 1mM infusion of NaNO2, which was then followed by a 3 
mM NaNO2 injection 15 minutes after the 1 mM injection. Doses were given at 15 
minute intervals with measurements taken in between.  A MAP measurement was taken 
immediately following the NaNO2 infusion then 1 minute after, 5 minutes after, and 10 
minutes after. Diameter measurements were taken 1 minute after, 5 minutes after, and 10 
minutes after. 
L-NAME 
 
For this portion of the study (n=6), a single 5 mg/kg dose of L-NAME was given 
to the rat followed by increasing doses of NaNO2: 100 µM, 1 mM, and 3 mM. Doses 
were given in 15 minute intervals with measurements taken in between. A MAP 
measurement was taken immediately after all infusions then 1 minute after, 5 minutes 
after, and 10 minutes after. Diameter measurements were taken 1 minute after, 5 minutes 
after, and 10 minutes after each infusion. 
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Table 1. Baseline physiological variables of all animals tested. 
  
 
 
 
 
 
 
Parameter HBOC (n = 20) NaNO2 (n=19) 
Weight (g) 287.7 ± 5.4 313.7 ± 8.2 
MAP (mmHg) 92.7 ± 3.7 87.1 ± 2.3 
PO2 (mmHg) 73.8 ± 3.8 80.4 ± 3.1 
PCO2 (mmHg) 42.3 ± 1.3 40.3 ± 1.6 
tHB (g/L) 15.8 ± 0.2 15.5 ± 0.3 
Hct (%) 
pH 
0.4 ± 0.005 
7.37 ± 0.01 
0.4 ± 0.004 
7.38 ± 0.01 
 
 
 
This table presents the physiological baselines for the rats prior to any infusions. Baseline 
measurements were taken to ensure the rat was in a stable, well maintained condition. 
MAP was taken using the CyQ 103/301 data acquisition and display system (CyberSense 
Inc., Nicholasville, KY). PO2 and PCO2 were measured on blood samples taken from the 
right femoral artery using an ABL 705 (Radiometer America Inc., Westlake OH). 
Hemoglobin concentration, tHB, was measured by a hemoximeter configured for rats 
(Radiometer OSM3, Radiometer, Crawley, West Sussex, UK). Percent hematocrit, Hct, 
was measured by capillary tube centrifugation.
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Results 
 
HBOC 
HSA 
 
 HSA was the volume control group that established a baseline for comparison 
with the rest of the HBOC experiments. The animals (n=2) showed little response to the 
increasing doses of HSA. There was no noticeable increasing trend with MAP, which 
stayed fairly constant and the baseline measurement. Vessel diameters of all three sizes 
show some fluctuations but none of them showed any significant change from baseline 
(Figure 1). The percent change indicates that MAP and diameter of all three arterioles 
showed no significant differences from baseline (Figure 2). 
 
Dose Dependent Effects HBOC 201 
 
 The initial doses of HBOC, 0.01 µM, 0.1 µM, and 1.0 µM, showed no significant 
changes from baseline. MAP showed no significant rise from baseline until the 100 µM 
dose. There was an increase at the time of the 10 µM injection, but was not significantly 
different from initial baseline. The diameters of all three arterioles showed no upward or 
downward trend and did not deviate significantly from baseline (Figure 3). There was a 
significant percent increase from baseline for MAP with the largest dose of 100 µM, but 
again diameters showed no significant change from baseline. Overall, MAP only 
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increased at the highest doses, but there was no change for any of the diameters (Figure 
4). 
Dose Dependent Effects of HBOC 205 (MW 400) 
 
 Increasing doses of HBOC 205 (MW 400) showed significant changes with 
respect to MAP. From the 10 µM dose, a steady increase was observed with each 
increasing dose of the HBOC. The MAP percent changes show a general trend of 
increasing change that is statistically significant from baseline. The greatest change was 
observed with the largest dose of 300 µM after 5 minutes. The arteriolar diameters failed 
to show any sort of change or trend in response to any of the doses (Figure 5). The 
percent change of diameter for each arteriole showed no significant changes from 
baseline (Figure 6). 
Dose-Dependent Effects of HBOC 205 (MW 600) 
 
 Increasing doses of HBOC 205 (MW 600) showed significant changes with 
respect to MAP. From the 100 µM dose, a steady increase was observed with each 
increasing dose of the HBOC. The MAP percent changes showed a general trend of 
increasing change that is statistically significant from baseline. The greatest change was 
observed with the second largest dose of 100 µM and remained elevated with the final 
dose of 300 µM. The arteriolar diameters failed to show any sort of change or trend in 
response to any of the doses (Figure 7). The percent change in diameter for each arteriole 
showed no significant changes from baseline (Figure 8). 
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Sodium Nitrite 
NaNO2 Control 
 
 The sodium nitrite control groups showed a decreasing trend with MAP, but little 
to no change with respect to arteriolar diameters. The decrease in MAP was a gradual 
drop with each increasing dose of NaNO2. The lowest MAP reading was found to be at 
the 10 minute mark after the final dose of 3 mM (Figure 9). There was a general trend of 
a decreasing percent change with significance from baseline for the 1 mM and 3 mM 
doses. Arteriolar diameters showed no significant change from baseline for any of the 
doses (Figure 10). 
NaNO2 Time Control 
 
 This study showed how long a single dose of 100 µM and 1 mM NaNO2 could 
last. The initial dose of 100 µM HBOC 201 showed a spike in MAP which was brought 
down to 117 mmHg 15 minutes after the 100 µM dose of NaNO2  (Figure 11). At the 25 
minute mark, MAP began to rise. Another dose of 1 mM brought MAP down to 105 
mmHg at the 10 minute mark but then began to rise again at the 15 minute mark. 
Arteriolar diameters showed no change or variation with any of the doses (Figure 12). 
HBOC 201 Time Control 
 
 The HBOC time control established the length of time that HBOC 201 from a 
single dose of 100 µM could exert its effects. An increase in MAP was noted 
immediately after the 100 µM injection, but no return to baseline was noted until the 60 
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minute mark. (Figure 13). Arteriolar diameters showed some small changes, but no 
definite trend was observed (Figure 14). 
NaNO2 Dose Response Effects following Single HBOC 201 Dose 
 
 There was a noticeable rise in MAP after the 100 µM dose of HBOC 201. After 
the initial 0.1 µM NaNO2 dose, there was a decreasing trend of the MAP with increasing 
doses of NaNO2. The largest drop in MAP was observed around the 100 µM dose. The 
arteriolar diameters showed no response to the HBOC or increasing doses of NaNO2. The 
percent change of MAP showed a significant increase from baseline after the HBOC 
infusion. The decreasing MAP percent change as a result of the NaNO2 infusion showed 
statistical significance compared with the initial HBOC response. Arteriolar diameters 
showed no statistically significant change from baseline or from the HBOC response 
(Figure 15). MAP showed an increase following the HBOC infusion and MAP decreased 
with increasing doses of the NaNO2; however, there was no diameter response in the 
arterioles (Figure 16). 
Simultaneous NaNO2 and HBOC effects 
 
 The initial dose of the HBOC showed a rise in MAP, but was quickly 
counteracted with the immediate 1 mM dose of NaNO2. The following dose of 3 mM 
NaNO2 showed a further decrease in MAP. The arteriolar diameters showed no response 
to the HBOC or any of the NaNO2 doses (Figure 17). Percent change of MAP showed a 
statistically significant change from baseline after the HBOC and NaNO2 simultaneous 
infusions, but showed a return to baseline following the increasing doses of NaNO2. 
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There was no statistical difference from baseline for the small arteriole, but there were 
statistical differences from baseline observed in the medium and large arterioles. In the 
medium arteriole an increase in percent change from baseline was observed after the 3 
mM NaNO2 dose, but a return to baseline occurred at the 10 minute marker. The large 
arteriole showed an increase in percent change from the baseline after the 1 mM dose, but 
returned to baseline after the 3 mM dose. Overall MAP showed a limited rise from the 
HBOC due to the presence of NaNO2, but even though significant percent changes were 
observed in some of the arterioles, no overall trends were observed (Figure 18). 
L-NAME and NaNO2 Dose Response Effects 
 
 The initial dose of L-NAME showed a very quick increase in MAP, peaking at 
the 5 minute mark after the infusion. Increasing doses of NaNO2 showed a steady 
decrease in MAP with a return to baseline after the 3 mM dose. Arteriolar diameters 
showed no significant changes or trends in response to the L-NAME or the NaNO2 
(Figure 19). The percent change of MAP showed a statistical difference from baseline 
with the infusion of the L-NAME and a steady drop in the increased percent change as 
the NaNO2 was administered. A return to baseline was observed 5 minutes after the final 
NaNO2 dose of 3 mM. There were no significant deviations from baseline observed in the 
diameter of any of the arterioles (Figure 20). 
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Figure 1.  HSA Dose Response Curve. The upper left graph represents the change in 
mean arterial pressure. The upper right graph represents the change in diameter of the 
small arteriole. The lower left graph represents the change in diameter of the medium 
arteriole. The lower right graph indicates the change in diameter of the large arteriole. 
The error bars represent standard error.  
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Figure 2  HSA Percent Change. The upper left graph represents the percent change in 
mean arterial pressure. The upper right graph represents the percent change in diameter of 
the small arteriole. The lower left graph represents the percent change in diameter of the 
medium arteriole. The lower right graph indicates the percent change in diameter of the 
large arteriole. The error bars represent standard error. An (*) represents significance at P 
< 0.05. An (**) represents significance at P < 0.01. An (***) represents significance at P 
< 0.001. 
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Figure 3.  HBOC-201 Dose Response Curve. The upper left graph represents the change 
in mean arterial pressure. The upper right graph represents the change in diameter of the 
small arteriole. The lower left graph represents the change in diameter of the medium 
arteriole. The lower right graph indicates the change in diameter of the large arteriole. 
The error bars represent standard error.  
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Figure 4.  HBOC-201 Percent Change. The upper left graph represents the percent 
change in mean arterial pressure. The upper right graph represents the percent change in 
diameter of the small arteriole. The lower left graph represents the percent change in 
diameter of the medium arteriole. The lower right graph indicates the percent change in 
diameter of the large arteriole. The error bars represent standard error. An (*) represents 
significance at P < 0.05. An (**) represents significance at P < 0.01. An (***) represents 
significance at P < 0.001. 
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Figure 5.  HBOC-205 (MW 400) Dose Response Curve. The upper left graph 
represents the change in mean arterial pressure. The upper right graph represents the 
change in diameter of the small arteriole. The lower left graph represents the change in 
diameter of the medium arteriole. The lower right graph indicates the change in diameter 
of the large arteriole. The error bars represent standard error.  
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Figure 6.  HBOC-205 (MW 400) Percent Change. The upper left graph represents the 
percent change in mean arterial pressure. The upper right graph represents the percent 
change in diameter of the small arteriole. The lower left graph represents the percent 
change in diameter of the medium arteriole. The lower right graph indicates the percent 
change in diameter of the large arteriole. The error bars represent standard error. An (*) 
represents significance at P < 0.05. An (**) represents significance at P < 0.01. An (***) 
represents significance at P < 0.001. 
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Figure 7.  HBOC-205 (MW 600) Dose Response Curve. The upper left graph represents 
the change in mean arterial pressure. The upper right graph represents the change in 
diameter of the small arteriole. The lower left graph represents the change in diameter of 
the medium arteriole. The lower right graph indicates the change in diameter of the large 
arteriole. The error bars represent standard error.  
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Figure 8.  HBOC-205 (MW 600) Percent Change. The upper left graph represents the 
percent change in mean arterial pressure. The upper right graph represents the percent 
change in diameter of the small arteriole. The lower left graph represents the percent 
change in diameter of the medium arteriole. The lower right graph indicates the percent 
change in diameter of the large arteriole. The error bars represent standard error. An (*) 
represents significance at P < 0.05. An (**) represents significance at P < 0.01. An (***) 
represents significance at P < 0.001. 
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Figure 9.  NaNO2 Control Dose Response Curve. The upper left graph represents the 
change in mean arterial pressure. The upper right graph represents the change in diameter 
of the small arteriole. The lower left graph represents the change in diameter of the 
medium arteriole. The lower right graph indicates the change in diameter of the large 
arteriole. The error bars represent standard error.  
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Figure 10.  NaNO2 Control Percent Change. The upper left graph represents the percent 
change in mean arterial pressure. The upper right graph represents the percent change in 
diameter of the small arteriole. The lower left graph represents the percent change in 
diameter of the medium arteriole. The lower right graph indicates the percent change in 
diameter of the large arteriole. The error bars represent standard error. An (*) represents 
significance at P < 0.05. An (**) represents significance at P < 0.01. An (***) represents 
significance at P < 0.001. 
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Figure 11.  NaNO2 Time Control Dose Response Curve. The upper left graph represents 
the change in mean arterial pressure. The upper right graph represents the change in 
diameter of the small arteriole. The lower left graph represents the change in diameter of 
the medium arteriole. The lower right graph indicates the change in diameter of the large 
arteriole. The error bars represent standard error.  
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Figure 12.  NaNO2 Time Control Percent Change. The upper left graph represents the 
percent change in mean arterial pressure. The upper right graph represents the percent 
change in diameter of the small arteriole. The lower left graph represents the percent 
change in diameter of the medium arteriole. The lower right graph indicates the percent 
change in diameter of the large arteriole. The error bars represent standard error. An (*) 
represents significance at P < 0.05. An (**) represents significance at P < 0.01. An (***) 
represents significance at P < 0.001. 
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Figure 13.  HBOC-201 Time Control Dose Response Curve. The upper left graph 
represents the change in mean arterial pressure. The upper right graph represents the 
change in diameter of the small arteriole. The lower left graph represents the change in 
diameter of the medium arteriole. The lower right graph indicates the change in diameter 
of the large arteriole. The error bars represent standard error.  
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Figure 14.  HBOC-201 Time Control Percent Change. The upper left graph represents 
the percent change in mean arterial pressure. The upper right graph represents the percent 
change in diameter of the small arteriole. The lower left graph represents the percent 
change in diameter of the medium arteriole. The lower right graph indicates the percent 
change in diameter of the large arteriole. The error bars represent standard error. An (*) 
represents significance at P < 0.05. An (**) represents significance at P < 0.01. An (***) 
represents significance at P < 0.001. 
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Figure 15. HBOC-201 + NaNO2 Dose Response Curve. The upper left graph represents 
the change in mean arterial pressure. The upper right graph represents the change in 
diameter of the small arteriole. The lower left graph represents the change in diameter of 
the medium arteriole. The lower right graph indicates the change in diameter of the large 
arteriole. The error bars represent standard error. 
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Figure 16.  HBOC-201 + NaNO2 Percent Change. The upper left graph represents the 
percent change in mean arterial pressure. The upper right graph represents the percent 
change in diameter of the small arteriole. The lower left graph represents the percent 
change in diameter of the medium arteriole. The lower right graph indicates the percent 
change in diameter of the large arteriole. The error bars represent standard error. An (*) 
represents significance at P < 0.05. An (**) represents significance at P < 0.01. An (***) 
represents significance at P < 0.001. 
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Figure 17.  HBOC-201 + NaNO2 Simultaneous Dose Response Curve. The upper left 
graph represents the change in mean arterial pressure. The upper right graph represents 
the change in diameter of the small arteriole. The lower left graph represents the change 
in diameter of the medium arteriole. The lower right graph indicates the change in 
diameter of the large arteriole. The error bars represent standard error.  
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Figure 18. HBOC-201 + NaNO2 Simultaneous Percent Change. The upper left graph 
represents the percent change in mean arterial pressure. The upper right graph represents 
the percent change in diameter of the small arteriole. The lower left graph represents the 
percent change in diameter of the medium arteriole. The lower right graph indicates the 
percent change in diameter of the large arteriole. The error bars represent standard error. 
An (*) represents significance at P < 0.05. An (**) represents significance at P < 0.01. An 
(***) represents significance at P < 0.001. 
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Figure 19. L-NAME + NaNO2 Dose Response Curve. The upper left graph represents 
the change in mean arterial pressure. The upper right graph represents the change in 
diameter of the small arteriole. The lower left graph represents the change in diameter of 
the medium arteriole. The lower right graph indicates the change in diameter of the large 
arteriole. The error bars represent standard error.  
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Figure 20. L-NAME + NaNO2 Percent Change. The upper left graph represents the 
percent change in mean arterial pressure. The upper right graph represents the percent 
change in diameter of the small arteriole. The lower left graph represents the percent 
change in diameter of the medium arteriole. The lower right graph indicates the percent 
change in diameter of the large arteriole. The error bars represent standard error. An (*) 
represents significance at P < 0.05. An (**) represents significance at P < 0.01. An (***) 
represents significance at P < 0.001. 
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Discussion 
 
HBOC 
Dose-Dependent Effects of the HBOCs 
 
 The results of the three HBOCs showed that MAP increased for nearly all of the 
HBOCs beginning at the 10 µM dose. Using HSA as a baseline comparison, it can be 
seen that for HBOC 201, a rising trend was noticed at the 10 µM dose, but was not 
significant until after the 100 µM dose. HBOC 205 (MW400) and HBOC 205 (MW 600) 
showed significant increases from baseline following the 10 µM injection and steadily 
increased with each dose up to 300 µM. These results confirm earlier observations that 
HBOC produces a hypertensive effect. Diameters of all three arterioles failed to show any 
sort of response that might indicate a vasoactive effect from any of the three HBOCs. 
(Figure 21). 
Comparison to Previous Literature 
 
 Based on previous literature, studies showed that HBOC has a hypertensive effect 
due to vasoconstriction. During a phase II clinical trial a group of 13 patients were 
administered small doses of HBOC 201. Measurements of HR, MAP, RAP and MPAP 
were monitored continuously during the study. Results showed an increase in mean 
arterial pressure which was due to an increase in systemic vascular resistance (Kasper 
1996). Other models have shown that HBOCs induce systemic vasoconstriction by  
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Figure 21.  HBOC 201, 205 (MW 400), and 205 (MW 600) Percent Change 
Comparison. The upper left graph represents the change in mean arterial pressure. The 
upper right graph represents the change in diameter of the small arteriole. The lower left 
graph represents the change in diameter of the medium arteriole. The lower right graph 
indicates the change in diameter of the large arteriole. The error bars represent standard 
error. 
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increasing the activity of vasoconstrictor molecules or decreasing the activity of the 
vasodilator molecules in the endothelial cells of the vascular wall (Hare 2006, Spahn 
2001, Surg 1996). Hare carried out studies on rats that were given doses of HBOCs to 
study their MAP response. Results showed an increase in MAP after the HBOC infusion 
confirming the HBOC’s hypertensive effect. Another study done by Meliagros, observed 
MAP and arterial diameter in the spinotrapezius muscle of rats in response to increasing 
doses of HBOCs. Using the same three HBOCs and same increasing doses, MAP and 
diameters were recorded at the same time points as this study. Similar effects were seen 
with MAP, but vasoconstriction was observed for all three HBOCs in the spinotrapezius. 
Other studies have found a lack of vasoactivity in the arterioles as well. Many in vivo 
studies have shown little evidence for vasoconstriction as well (Spahn 1994). 
 
Sodium Nitrite 
Dose-Dependent Effects of NaNO2 following  HBOC 201 Infusion 
 
 The results indicated that sodium nitrite was effective at decreasing MAP 
following the administration of HBOC-201. After the initial dose of the HBOC, 
increasing doses of sodium nitrite were able to return MAP back to baseline by the end of 
the experiment. These results indicate that the mechanism of vasoactivity of the HBOC is 
due to the NO scavenging effects of the HBOC. The return to baseline with increasing 
doses of NaNO2 indicates that NO that was scavenged by the HBOC was restored 
allowing a decrease in vascoconstriction. If the HBOC caused an increase in MAP by an 
alternative mechanism, such as increased oxygen delivery, the doses of NaNO2 should 
  
73
 
have had no effect on MAP after the HBOC 201 dose. The simultaneous infusion of the 
HBOC and NaNO2 showed that the NaNO2 was able to prevent MAP from rising as high 
as it would have if just the HBOC had been administered alone. There was a brief rise in 
MAP after the HBOC infusion, but immediately after the NaNO2 was administered, the 
rise in MAP was inhibited and there was a gradual decline to baseline. This shows that 
the NaNO2 was able to prevent the HBOC from scavenging the NO in the endothelium of 
the arteriolar wall. Studies with NaNO2 confirm the theory that NO scavenging is the 
mechanism by which the HBOC causes vasoconstriction. Even though changes in MAP 
were observed with the NaNO2 doses, no changes in arteriolar diameters were observed. 
There was no vasoconstriction observed with the administration of HBOC 201 or a 
vasodilation with the administration of NaNO2. 
L-NAME and NaNO2 Effects 
 
 Because L-NAME is a NOS inhibitor, it should be able to decrease NO levels by 
the inhibiting the synthesis of NO. The sudden inhibition of NOS causes a drop in NO 
level leading to vasoconstriction and an increase in MAP. Although L-NAME does not 
directly affect levels of NO, it should have similar effects to scavenging of the NO by 
HBOC-201. The studies with L-NAME showed that L-NAME had very similar effects to 
that of the HBOC. The increase in MAP caused by L-NAME was similar to that of the 
increase from the HBOC. After the L-NAME injection, sodium nitrite was able to return 
MAP back to baseline. Because L-NAME has such similar effects to HBOC-201, it 
would indicate that HBOC-201 does in fact cause an increase in MAP due to its NO 
scavenging effects. The fact that L-NAME caused similar effects to HBOC-201 further 
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supports the theory that increased oxygen transport is not the mechanism of HBOC-
induced vasoconstriction.  
No vasoactivity was observed in the mesentery as a result of the L-NAME 
infusion or the following NaNO2 doses. Looking at the results, it would seem that NO 
does not seem to play a major role in regulating vascular tone of the mesenteric arteries. 
Infusion of NaNO2 or L-NAME had no effect on constricting or dilating any of the 
arterioles observed. One explanation for this is that the mesentery does not produce a 
significant amount of NO in the first place. Another possible explanation would be to 
assume the mesentery is not very sensitive to levels of NO. These two explanations 
actually help explain each other. If the mesentery does not produce a high level NO in the 
first place, it could be assumed that the mesentery therefore would not need to be 
sensitive to levels of NO leaving it unresponsive to any concentrations of circulating NO. 
Although NO is a potent vasodilator, there are several other factors such as prostacylcin 
that might play a role in the mesentery (Feletou 2006). Additionally, it is possible that the 
preparation of the mesentery rendered it unresponsive to any vasodilators or 
vasoconstrictors. 
Comparisons to Previous Literature 
 
 Several studies have been done to show that the mechanism of vasoconstriction 
by HBOCs is in fact due to NO scavenging. Studies done by Olson looked at the pathway 
by which extracellular HbO2 is able to cause vasoconstriction. Olson looked at the effects 
of extracellular hemoglobin and its NO scavenging effects. Looking at the side effects of 
many HBOCs, hypertension and gastrointestinal dysmotility, it seems that HBOCs are 
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potent NO scavengers since the side effects can be explained by decreasing levels of NO. 
Observing the cardiac output in addition to the blood pressure showed that the rise in 
MAP was proportional to TPR. This would indicate that a systemic vasoconstricion was 
occurring to cause the increase in MAP. Extracellular hemoglobin is free to extravasate 
into the endothelial wall scavenging the NO and causing vasoconstriction (Olson 2004). 
A study done by Hare showed that an increased molecular weight of the hemoglobin 
decreased its vasoactive effects. The increase in molecular weight prevents extravasation 
into the endothelial wall, which would decrease extracellular hemoglobin’s vasoactive 
effects. By not being able to extravasate, the hemoglobin was unable to scavenge NO. A 
decrease in MAP rise because of a larger hemoglobin molecule supports the theory that 
HBOCs produce an increase in MAP by acting as a NO sink (Hare 2006, Gould 1996). 
 Few studies have been done to observe the NO activity of the mesentery in vivo or 
in vitro. One study done examined the concentration of NO found in the mesentery. 
Tschudi observed direct in situ measurements of NO in the mesentery of rats and found 
that the level of NO in the mesentery compared to that of the aorta was drastically lower. 
In addition, it was observed that the NOS activity of the mesentery was reduced 
compared to that of the aorta (Tschudi 1996). A study done by Mitchell looked 
specifically at the mesenteric arteries and their response to varying levels of NO. She 
used LPS to induce NOS and observe the response of the mesentery to other 
vasoconstrictors. What she found was that the increased activity of NOS did not show a 
reduced responsiveness to vasoconstrictor agents (Mitchell 1993). These studies support 
the idea that NO may not be a major factor in regulating the vascular tone of the 
mesenteric arteries. 
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Further Studies 
 
 Further studies observing mesenteric vasoactivity would be of great benefit. It 
would be useful to know which factors vary vascular tone in the mesentery. Also it could 
show that the mesentery preparation responds to vasoactive factors. This could be done 
by topically applying other vasoconstrictors and other vasodilators that do not alter NO 
levels, such as papaverine. It would also be of some interest if NO electrodes could be 
used to establish a baseline for in vivo measurements of NO and see if the HBOC is 
causing a drop in NO. 
Conclusion 
 
 Even though no vasoactivity was observed in the mesentery, the MAP results 
support the theory of NO scavenging. Just because the mesentery did not respond to the 
HBOCs, NaNO2, or L-NAME does not rule out vasoconstriction at other sites, such as 
skeletal muscle. The increase in MAP points to a systemic vasoconstriction, but the 
diameters of arterioles in the mesentery indicate that NO will not affect local vascular 
tone in the mesentery. Looking together at the results of the various HBOCs, NaNO2, and 
L-NAME, it would seem that NO scavenging is the major factor in the vasoconstrictor 
side effect of HBOCs, but there are remaining studies to look at mesenteric vasoactivity. 
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APPENDIX 
APPENDIX I – Data Experimental Protocol 
Michael Kim (__________________)  
 
Date: __________  Card #:_________           Rat Weight:__________ 
 
Ketamine (__________/__________) 
 
Alfaxin (__________)  Syringe #:__________     Amount: _____-______ 
 
Start Time: __________ 
        Notes: 
Femoral Vein: __________ 
 
Femoral Artery: __________ 
 
Tracheotomy: __________ 
 
Jugular Vein: __________ 
 
Scope: __________ 
 
 MAP S M L 
Initial     
Baseline     
0.01 uM     
1 min     
5 min     
10 min     
0.1 uM     
1 min     
5 min     
10 min     
1 uM     
1 min     
5 min     
10 min     
10 uM     
1 min     
5 min     
10 min     
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100 uM     
1 min     
5 min     
10 min     
 
APPENDIX II – Physiological Baselines 
 Weight MAP PO2 PCO2 tHB Hct pH 
HAS 1 260 112 66.2 49.5 15.4 0.39 7.325 
HAS 2 297.5 123.4 91.2 37 16 0.39 7.327 
HBOC 1 291 117.8 106 53.1  0.44 7.278 
HBOC 2 283 123 93.2 44.1  0.42 7.357 
HBOC 3 278 95.4 69.6 42.6 14 0.4 7.395 
HBOC 4 297 85.7 59 37 16.9 0.42 7.398 
HBOC 5 315 109.5 60.1 41.1 17.2 0.45 7.396 
HBOC 6 315       
HBOC 6-1 244 91.5 79.6 41.4 16.3 0.43 7.401 
HBOC 6-2 248 86.5 70.2 36.5 16.3 0.38 7.438 
HBOC 6-3 259 85.4 42.5 33.6 16 0.39 7.419 
HBOC 6-4 299 86.5 87.8 38 15.6 0.38 7.411 
HBOC 6-5 295 80.8 70.2 38.4 17.1 0.42 7.382 
HBOC 6-6 257 70.8 58.6 46.2 15.4 0.39 7.34 
HBOC 4-1 323 81.4 53.6 35.8 17.1 0.39 7.434 
HBOC 4-2 323 81.9 92.8 44.5 15.4 0.38 7.37 
HBOC 4-3 276 82.8 82.9 46 15.2 0.38 7.367 
HBOC 4-4 292 77.1 89.4 42 13.9 0.39 7.386 
HBOC 4-5 290 88.5 65.3 49.6 15.4 0.39 7.362 
HBOC 4-6 312 80.9 63.6 48 15.6 0.39 7.279 
Average 287.725 92.68 73.779 42.337 15.812 0.4011 7.37184211 
Std. Error 5.4 3.7 3.8 1.3 0.2 0.005 0.01 
        
        
        
NO Ctrl 1 278 92.1 88.7 37.8 13.7 0.4 7.403 
NO Ctrl 2 330 88.3 78.7 36.5 16.3 0.39 7.414 
HBOC Time 1 308 81.5 49.6 28.8 16.6 0.4 7.506 
HBOC Time 2 311 80.9 62.2 44.9 16.1 0.39 7.423 
NO Time 347 102.1   15 0.4  
HBOC/NO 1 279 84.8 76.1 50.1 15.3 0.41 7.319 
HBOC/NO 2 297 80.8 78.9 37.8 14.5 0.39 7.355 
HBOC/NO 3 299 81.3 89.3 32.6 15.9 0.4 7.452 
HBOC/NO 4 297 112.9 84.7 36.8 14.5 0.42 7.424 
HBOC/NO 5 300 90.1 73.7 49.9 14.3 0.39 7.369 
HBOC/NO 6 378 80.4 75 42.6 15.7 0.41 7.371 
HBOC+NO 1 347 103.7 82.8 36.2 16.2 0.44 7.427 
HBOC+NO 2 343 82.1 101 43.4 17 0.4 7.337 
LNAME 1 342 81.5 81.7 33.3 16 0.41 7.344 
LNAME 2 240 88.6   16.8 0.38  
LNAME 3 335 79 66.6 47.6 15.7 0.38 7.353 
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LNAME 4 347 89.1 90.7 48.2 16 0.4 7.37 
LNAME 5 332 73.4 93 42.8 16.8 0.38 7.365 
LNAME 6 251 81.9 94.2 35.8 12.3 0.38 7.388 
Average 313.7 87.1 80.4 40.3 15.5 0.4 7.38 
Std. Error 8.2 2.3 3.1 1.6 0.3 0.0035 0.01 
 
APPENDIX III - Data 
Average MAP     
Human Albumin Serum Ctrl   
     
 #1 #2 Average
Std. 
Error 
 MAP MAP MAP MAP 
Initial  112.0 125.0 118.5 6.5
Baseline 112.6 123.4 118.0 5.4
0.01uM 115.3 124.5 119.9 4.6
1 min 125.0 123.6 124.3 0.7
5 min 123.0 122.1 122.6 0.45
10 min 114.0 116.9 115.5 1.45
0.1uM 101.6 113.9 107.8 6.15
1 min 102.2 113.5 107.9 5.65
5 min 107.0 109.5 108.3 1.25
10 min 104.4 108.5 106.5 2.05
1uM 105.9 107.0 106.5 0.55
1 min 109.1 106.9 108.0 1.1
5 min 108.3 107.0 107.7 0.65
10 min 108.1 104.4 106.3 1.85
10uM 105.1 104.9 105.0 0.1
1 min 104.3 103.9 104.1 0.2
5 min 102.2 100.3 101.3 0.95
10 min 102.1 99.5 100.8 1.3
100uM 110.1 97.4 103.8 6.35
1 min 108.3 96.3 102.3 6
5 min 105.8 95.8 100.8 5
10 min 106.4 94.7 100.6 5.85
 
Average 
Large     
Human Albumin Serum Ctrl   
     
 #1 #2 Average
Std. 
Error 
 S S S S 
Initial  29.85  29.9
2.8E-
308
Baseline 32.51 24.07 28.3 4.22
0.01uM        
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1 min 31.79 22.36 27.1 4.715
5 min 31.62 23.31 27.5 4.155
10 min 29.8 23.64 26.7 3.08
0.1uM        
1 min 35.29 22.95 29.1 6.17
5 min 35.41 23.76 29.6 5.825
10 min 36.48 23.17 29.8 6.655
1uM        
1 min 38.39 21.8 30.1 8.295
5 min 39.14 25.16 32.2 6.99
10 min 37.36 25.52 31.4 5.92
10uM        
1 min 37.12 25.31 31.2 5.905
5 min 38.89 25.21 32.1 6.84
10 min 38.33 25.26 31.8 6.535
100uM        
1 min 40.21 25.58 32.9 7.315
5 min 39.58 24.56 32.1 7.51
10 min 36.87 25.15 31.0 5.86
 
Average Medium    
Human Albumin Serum Ctrl   
     
 #1 #2 Average
Std. 
Error 
 M M M M 
Initial  271.42  271.4
2.8E-
308
Baseline 244.51 28.74 136.6 107.885
0.01uM        
1 min 274.2 28.58 151.4 122.81
5 min 281.77 28.09 154.9 126.84
10 min 271.5 28.62 150.1 121.44
0.1uM        
1 min 256.09 27.75 141.9 114.17
5 min 281.4 27.39 154.4 127.005
10 min 282.79 29.01 155.9 126.89
1uM        
1 min 273.65 30.03 151.8 121.81
5 min 272.77 29.37 151.1 121.7
10 min 269.66 29.12 149.4 120.27
10uM        
1 min 267.52 28 147.8 119.76
5 min 273.06 29.71 151.4 121.675
10 min 273.32 29.35 151.3 121.985
100uM        
1 min 290.86 29.71 160.3 130.575
5 min 271.33 30.27 150.8 120.53
10 min 291.67 31.23 161.5 130.22
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Average 
Large     
Human Albumin Serum Ctrl   
     
 #1 #2 Average
Std. 
Error 
 L L L L 
Initial  357.79  357.8
2.8E-
308
Baseline 333.51 280.47 307.0 26.52
0.01uM        
1 min 351.91 289.43 320.7 31.24
5 min 342.9 275.44 309.2 33.73
10 min 323.21 308.42 315.8 7.395
0.1uM        
1 min 309.61 315.09 312.4 2.74
5 min 322.66 297.23 309.9 12.715
10 min 323.21 300.95 312.1 11.13
1uM        
1 min 358.15 306.02 332.1 26.065
5 min 350.53 285.7 318.1 32.415
10 min 353.02 295.78 324.4 28.62
10uM        
1 min 356.72 283.67 320.2 36.525
5 min 354.19 261.65 307.9 46.27
10 min 358.94 279.66 319.3 39.64
100uM        
1 min 352.08 276.56 314.3 37.76
5 min 331.05 281.37 306.2 24.84
10 min 350.62 301.81 326.2 24.405
 
Average MAP         
HBOC 201         
         
 #1 #2 #3 #4 #5 #6 Average 
Std. 
Error 
 MAP MAP MAP MAP MAP MAP MAP MAP 
Initial  103.5 97.9 105.1 86.6 88.9 105 97.8 3.377738
Baseline 107.8 123.0 95.4 85.7 92.9 109.5 102.4 5.543971
0.01uM 115.8 111.4 98.1 92.1 103.8 104.1 104.2 3.512778
1 min 110.0 115.3 97.3 90.1 95.3 98.5 101.1 3.901659
5 min 95.5 113.6 96 88.8 89.3 102.5 97.6 3.800475
10 min 101.3 126.0 95.6 87.1 83.5 99.6 98.9 6.131707
0.1uM 101.3 123.0 104.6 89 84.5 97.5 100.0 5.535788
1 min 95.5 125.0 102.1 90.1 86.7 99.5 99.8 5.551601
5 min 90.4 121.0 90.5 89.3 88.3 108.6 98.0 5.553222
10 min 83.5 118.0 90.1 95.6 95.2 95.6 96.3 4.744658
1uM 111.5 118.7 95.1 95.3 88.6 105.3 102.4 4.658499
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1 min 104.5 120.3 98.1 102.3 95.3 108.6 104.9 3.633891
5 min 98.6 120.8 105 88.1 80.3 105.3 99.7 5.821765
10 min 87.5 123.7 103.5 90.7 83.6 103.6 98.8 6.026257
10uM 119.5 125.4 110.5 100.7 95.6 98.5 108.4 4.95901
1 min 122.6 123.4 128.5 98.7 98.7 95.6 111.3 6.147994
5 min 124.5 120.9 122.7 100.7 105.7 98.7 112.2 4.809643
10 min 121.5 118.5 96.3 105.6 104.3 95.4 106.9 4.475017
100uM 153.5 135.6 105.3 119.6 105.3 120.3 123.3 7.60266
1 min 142.7 137.4 138.5 128.7 110.3 132.8 131.7 4.71838
5 min 136.5 138.1 135.6 127.5 130.5 135.6 134.0 1.660054
10 min 126.5 137.1 130.6 125.3 125.5 100.3 124.2 5.121095
 
Average 
Small          
HBOC 201         
         
 #1 #2 #3 #4 #5 #6 Average Std. Dev 
 S S S S S S S S 
Initial  8.88 11.49 9.6 15.18 5.79 5.65 9.4 1.473946
Baseline 10.49 9.88 9.925 15.73 4.16 5.65 9.3 1.665632
0.01uM                
1 min 7.42 10.11 9.874 14.54 5.97 9.46 9.6 1.192744
5 min 7.67 11.26 9.98 13.57 5.59 6.68 9.1 1.233404
10 min 11.23 9.88 10.83 16.52 4.42 5.25 9.7 1.805941
0.1uM                
1 min 8.7 8.73 8.81 15.98 4.74 4.53 8.6 1.693103
5 min 9.54 8.36 10.81 15.64 7.98 5.96 9.7 1.357468
10 min 8.81 8.73 11.122 15.78 6.58 5.45 9.4 1.505775
1uM                
1 min 8.31 9.88 8.87 15.65 5.64 7.2 9.3 1.409717
5 min 6.47 9.66 9.525 14.6 4.91 6.07 8.5 1.443502
10 min 6.13 9.67 9.887 10.12 4.46 6.93 7.9 0.964538
10uM                
1 min 8.98 9.66 9.972 12.68 5.37 5.14 8.6 1.185952
5 min 7.71 11.03 10.28 19.35 6.31 8.09 10.5 1.913037
10 min 6.22 10.81 10.18 20.35 5.69 6.79 10.0 2.243356
100uM                
1 min 5.98 9.2 8.15 11.71 4.58 8.5 8.0 1.020637
5 min 5.48 9.88 8.968 8.19 6.67 7.61 7.8 0.646481
10 min 6.39 9.2 10.57 15.64 4.39 6.76 8.8 1.627806
 
Average Medium        
HBOC 201         
         
 #1 #2 #3 #4 #5 #6 Average Std. Dev 
 M M M M M M M M 
Initial  12.44 24.67 22.64 26.22 18.22 21.06 20.9 2.035671
Baseline 11.68 29.93 22.76 29.07 18.19 22.07 22.3 2.792783
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0.01uM                
1 min 11.45 28.7 21.1 29.22 15.92 20.69 21.2 2.850608
5 min 12.92 29.12 20.92 27.68 16.01 20.23 21.1 2.58981
10 min 12.1 26.88 21.9 29.34 19.02 20 21.5 2.498805
0.1uM                
1 min 10.81 26.87 23.33 32.5 18.28 22.53 22.4 3.023101
5 min 12.56 28.61 20.37 31.09 18.71 21.15 22.1 2.766449
10 min 12.31 26.67 21.53 33.07 18.9 21.15 22.3 2.87727
1uM                
1 min 13.29 26.43 22.46 28.11 17.31 20.92 21.4 2.266986
5 min 11.4 29.22 23.46 27.5 16.01 20.69 21.4 2.781845
10 min 11.36 29.08 23.25 29.35 14.4 21.38 21.5 3.029741
10uM                
1 min 10.92 28.31 22.5 31.23 15.03 20.92 21.5 3.142087
5 min 11.63 26.74 22.8 29.98 18.74 18.62 21.4 2.672994
10 min 10.28 29.62 23.46 29.66 17.91 20.69 21.9 3.025724
100uM                
1 min 9.98 31.06 21.47 29.05 17.88 17.24 21.1 3.222123
5 min 10.11 31.9 22.67 29.28 16.71 18.75 21.6 3.317964
10 min 10.5 27.25 23.88 29.95 14.57 21.61 21.3 3.049099
 
Average 
Large         
HBOC 201         
         
 #1 #2 #3 #4 #5 #6 Average 
Std. 
Error 
 L L L L L L L L 
Initial  223.59 273.15 228.05 228.05 209.56 203.97 227.7 9.958258
Baseline 182.91 279.23 227.25 227.25 205.39 200.86 220.5 13.62276
0.01uM                
1 min 173.91 274 220.49 220.49 198.91 206.84 215.8 13.60337
5 min 145.98 272.05 230.17 230.17 184.51 212.36 212.5 17.68146
10 min 140.64 276.06 220.29 220.29 235.02 179.94 212.0 19.05355
0.1uM                
1 min 175.78 272.2 229.56 229.56 221.95 178.57 217.9 14.78483
5 min 169.91 266.79 238.44 238.44 232.65 169.36 219.3 16.43124
10 min 160.97 275.48 210.59 210.59 209.82 197.36 210.8 15.10873
1uM                
1 min 185.91 273.61 221.12 221.12 219.87 202.35 220.7 12.03823
5 min 183.9 258.96 210.59 210.59 219.84 201.43 214.2 10.23473
10 min 198.62 276.58 224.86 224.86 224.65 201.58 225.2 11.40882
10uM                
1 min 162.76 281.48 221.47 221.47 227.92 202.07 219.5 15.75162
5 min 153.95 285.58 220.74 220.74 223.94 200.07 217.5 17.35873
10 min 183.54 275.3 218.56 218.56 201.49 200.87 216.4 12.93807
100uM                
1 min 169.5 269.31 230.53 230.53 225.78 167.48 215.5 16.20176
5 min 152.57 251.6 225.24 225.24 225.37 188.89 211.5 14.33169
10 min 157.41 282.5 227.98 227.98 226.84 184.36 217.8 17.55017
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Average Map         
HBOC 205         
MW 400         
 #1 #2 #3 #4 #5 #6 Average 
Std. 
Error 
 MAP MAP MAP MAP MAP MAP MAP MAP 
Initial  80.1 89.9 89.3 85.3 83.1 80.7 84.7 1.715355
Baseline 81.4 81.9 82.8 77.1 88.5 80.9 82.1 1.510188
1uM 83.4 89.3 82.0 84.1 89.3 81.2 84.9 1.457262
1 min 91.4 95.4 83.9 88.3 90.1 83.1 88.7 1.903506
5 min 92.1 91.1 84.6 91.3 87.3 83.1 88.3 1.559861
10 min 81.2 87.3 83.9 83.0 90.3 81.1 84.5 1.489221
10 uM 93.4 98.7 89.3 84.5 93.6 85.3 90.8 2.230097
1 min 102.3 112.6 101.3 89.1 96.5 87.7 98.3 3.784684
5 min 118.3 117.8 115.9 96.7 96.0 89.9 105.8 5.272297
10 min 122.1 109.3 112.1 99.6 99.8 93.0 106.0 4.303906
100 uM 134.7 113.8 110.1 100.8 98.3 95.4 108.9 5.919727
1 min 137.3 125.3 120.4 110.3 101.4 109.4 117.3 5.283661
5 min 140.1 133.5 130.5 115.1 118.5 115.7 125.6 4.302454
10 min 129.1 131.4 125.6 116.7 111.2 112.8 121.1 3.543037
300 uM 134.1 132.3 124.3 120.8 115.4 114.0 123.5 3.433115
1 min 148.1 135.6 131.3 125.7 124.8 119.4 130.8 4.14145
5 min 138.9 134.8 145.3 135.0 131.2 129.8 135.8 2.299662
10 min 128.1 129.7 138.3 131.2 129.8 125.4 130.4 1.771895
 
Average Small Vessel Diameter       
HBOC 205         
MW 400         
 #1 #2 #3 #4 #5 #6 Average 
Std. 
Error 
 S S S S S S S S 
Initial  20.23 30.29 33.06 33.06 28.95 12.04 26.3 3.437661
Baseline 26.58 25.56 36.06 36.06 31.29 10.13 27.6 3.946142
1uM                
1 min 28.98 29.69 37.38 37.38 34.26 11.68 29.9 3.93179
5 min 22.6 27.23 39.07 39.07 33.11 13.29 29.1 4.125434
10 min 23.18 27.42 37.38 37.38 33.46 13.21 28.7 3.853079
10 uM                
1 min 18.83 28.98 32.64 32.64 34.36 12.8 26.7 3.603645
5 min 23.89 28.76 34.07 34.07 33.62 12.46 27.8 3.483402
10 min 18.9 27.93 35.1 35.1 33.19 11.04 26.9 4.044096
100 uM                
1 min 23.4 26.78 33.86 33.86 33.19 13.05 27.4 3.36295
5 min 24.3 29.32 33.67 33.67 32.1 12.85 27.7 3.293097
10 min 21.76 29.03 33.91 33.91 31.87 11.78 27.0 3.570382
300 uM                
1 min 22.86 30.03 37.5 37.5 33.1 14.5 29.2 3.696622
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5 min 24.39 30.42 36.47 36.47 33.03 10.89 28.6 3.992403
10 min 22.58 28.89 33.53 33.53 31.72 12.45 27.1 3.377818
 
Average Medium Vessel Diameter       
HBOC 205         
MW 400         
 #1 #2 #3 #4 #5 #6 Average 
Std. 
Error 
 M M M M M M M M 
Initial  161.63 301.8 223.26 248.86 207.52 162.53 217.6 21.88288
Baseline 167.46 306.51 277.58 278.65 222.26 201.84 242.4 21.85446
1uM                
1 min 165.15 307.58 286.82 293.54 226.99 147.17 237.9 28.27708
5 min 162.79 304.81 302.17 282.02 219.6 195.17 244.4 24.56341
10 min 163.96 300.61 276.13 295.58 227.08 223.62 247.8 21.53876
10 uM                
1 min 162.89 294.7 278.22 280.84 221.24 201.78 239.9 21.50923
5 min 172.14 295.37 304.44 276.21 224.13 231.41 250.6 20.64288
10 min 155.09 285.59 276.77 302.97 225.5 220.41 244.4 22.42312
100 uM                
1 min 140.53 231.78 294.86 285.4 218.89 198.5 228.3 23.36872
5 min 165.49 244.37 294.83 296.78 229.14 201.48 238.7 21.12852
10 min 163.01 247.06 314.07 301.87 221.34 187.45 239.1 24.76338
300 uM                
1 min 179.58 257.8 315.84 295.74 238.88 215.48 250.6 20.62387
5 min 168.31 256.4 331.01 289.45 243.17 198.47 247.8 24.15653
10 min 155.5 286.78 300.57 298.42 231.81 202.78 246.0 24.25443
  
Average Large Vessel Diameter       
HBOC 205         
MW 400         
 #1 #2 #3 #4 #5 #6 Average 
Std. 
Error 
 L L L L L L L L 
Initial  208.59 353.89 355.7 339.08 296 314.05 311.2 22.61854
Baseline 218.89 351.34 366.6 359.83 245.47 296.9 306.5 25.79345
1uM                
1 min 202.33 359.14 314.17 357.8 278.15 278.42 298.3 24.1558
5 min 215.88 360.18 347.08 353.94 271.73 266.28 302.5 24.3051
10 min 217.48 360.67 340.61 358.74 282.45 300.16 310.0 22.58007
10 uM                
1 min 222.5 368.59 375.94 361.8 284.95 285.46 316.5 25.22793
5 min 209.6 303.41 363.8 362.08 275.22 304.09 303.0 23.58228
10 min 213.2 329.6 377.94 352.24 311.8 296.44 313.5 23.28557
100 uM                
1 min 197.3 303.67 361.75 358.71 314.8 297.84 305.7 24.39326
5 min 189.03 331.79 401.49 364.84 306.19 289.64 313.8 29.90397
10 min 204.14 289.89 383.2 351.24 295.14 297.43 303.5 25.03036
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300 uM                
1 min 200.38 261.04 395.8 356.28 302.11 295.41 301.8 28.16167
5 min 205.79 312.41 379.94 349.54 288.94 288.04 304.1 24.52085
10 min 208.64 300.41 404.6 384.25 315.6 301.14 319.1 28.54255
 
Average MAP         
HBOC 205 
MW 
600        
         
 #1 #2 #3 #4 #5 #6 Average Std. Dev 
 MAP MAP MAP MAP MAP MAP MAP MAP 
Initial  98.8 84.4 89.1 88.9 89.8 75.3 87.7 3.139365
Baseline 91.5 86.5 85.4 80.5 80.8 70.8 82.6 2.88183
10uM 112.5   83.2 89.8 116.1 85.3 97.4 7.012517
1 min 123.5  81.5 94.1 106.7 90.5 99.3 7.285987
5 min 117.5  78.5 81.5 88.6 70.5 87.3 8.084083
10 min 112.6  77.8 76.3 79.1 70.6 83.3 7.472175
100 uM 146.5 126.5 126.9 110.6 118.7 105.3 122.4 5.953174
1 min 160.2 129.5 128.3 111.7 126.7 107.3 127.3 7.598176
5 min 154.6 83.4 124.6 130.4 125.5 104.3 120.5 9.901975
10 min 153.5 79.5 116.1 118.5 115.8 88.6 112.0 10.64512
300 uM 161 120.5 116.5 124.7 131.8 103.5 126.3 7.929719
1 min 163.2 134.5 113.8 131.8 132.2 108.5 130.7 7.858315
5 min 154.5 140.6 107.3 121.4 125.3 101.5 125.1 8.148906
10 min 155.3 140.3 117.8 113.5 110.3 99.5 122.8 8.511029
 
Average 
Small         
HBOC 205 
MW 
600        
         
 #1 #2 #3 #4 #5 #6 Average Std. Dev 
 S S S S S S S S 
Initial  6.25 13.84 26.98 10.04 18.51 20.17 16.0 3.052276
Baseline 7.48 11.73 29.16 8.68 20.14 17.6 15.8 3.35185
10uM                
1 min 7.31  27.71 10.81 17.38 21.97 17.0 3.686157
5 min 7.35  26.71 12.78 19.49 21.58 17.6 3.396306
10 min 8.87  30.3 13.15 20.02 20.1 18.5 3.643275
100 uM                
1 min 9.67 9.06 27.76 12.51 17.9 22.67 16.6 3.080503
5 min 10.09 13.89 27.17 11.87 20.91 21.55 17.6 2.715009
10 min 10.08 14.92 27.34 11.87 21.58 23.34 18.2 2.817472
300 uM                
1 min 6.19 11.84 29.17 10.72 19.7 21.36 16.5 3.443876
5 min 8.07 12.87 28.18 11.94 19.63 22.72 17.2 3.091395
10 min 9.48 10.87 27.16 11.66 18.46 21.82 16.6 2.88761
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Average Medium        
HBOC 205 MW 600        
         
 #1 #2 #3 #4 #5 #6 Average
Std. 
Error 
 M M M M M M M M 
Initial  21.62 44.84 168.72 47.31 175.95 180.56 106.5 30.92439
Baseline 19.7 44.84 186.14 45.14 202.18 207.44 117.6 36.53839
10uM                
1 min 16.85  172.74 46.66 185.41 198.67 124.1 38.20011
5 min 17.09  183.37 48.17 174.34 197.67 124.1 37.85897
10 min 18.02  165.78 45.54 173.93 206.87 122.0 37.73215
100 uM                
1 min 19.73 42.99 171.15 46.76 184.02 203.41 111.3 33.94662
5 min 22.47 36.79 168.13 48.2 185.67 205.9 111.2 34.22171
10 min 19.39 42.26 159.08 47.75 186.71 209.36 110.8 34.07647
300 uM                
1 min 20.65 41.85 166.99 45.91 167.64 192.73 106.0 31.65017
5 min 16.46 40.89 172.79 46.62 181.6 146.37 100.8 30.2356
10 min 20.13 39.54 171.5 47.81 160.6 152.16 98.6 28.43257
 
Average 
Large         
HBOC 205 
MW 
600        
         
 #1 #2 #3 #4 #5 #6 Average
Std. 
Error 
 L L L L L L L L 
Initial  276.58 248.09 243.13 331.45 256.41 260.16 269.3 13.29166
Baseline 283.95 250.33 238.72 268.48 259.88 245.15 257.8 6.787408
10uM                
1 min 279.32  256.41 271.3 250.89 252.73 262.1 5.599112
5 min 281.45  251.55 277.68 234.82 232.12 255.5 10.38085
10 min 284.5  243.13 235.61 244.49 227.18 247.0 9.874436
100 uM                
1 min 266.47 236.06 292.76 241.1 244.54 239.07 253.3 9.047692
5 min 272.5 241.1 227.59 247.22 225.3 243.56 242.9 6.934578
10 min 276.66 253.53 226.58 244.05 235.11 228.79 244.1 7.683847
300 uM                
1 min 288.8 253.53 214.52 244.57 233.72 223.56 243.1 10.77968
5 min 285.14 243.1 216.87 261.47 240.62 163.58 235.1 17.06975
10 min 275.12 248.56 218.54 248.09 233.12 161.58 230.8 15.83847
 
Average MAP Arterial    
 NaNO2 Ctrl   
     
 #1 #2 Average  
 MAP MAP MAP Std. 
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Error 
Initial  81.3 86.4 83.9 2.55
Baseline 92.1 88.3 90.2 1.9
10uM 91.2 88.1 89.7 1.55
1 min 90.8 86 88.4 2.4
5 min 87.3 88.5 87.9 0.6
10 min 88.2 89.4 88.8 0.6
100uM 89.3 85 87.2 2.15
1 min 82.1 86.1 84.1 2
5 min 80.1 91.5 85.8 5.7
10 min 62.4 86.5 74.5 12.05
1mM 83.4 87.9 85.7 2.25
1 min 85 78.3 81.7 3.35
5 min 77 82.4 79.7 2.7
10 min 82 85.4 83.7 1.7
3mM 78.3 80.3 79.3 1
1 min 83.9 78.3 81.1 2.8
5 min 79.6 73.3 76.5 3.15
10 min 82 62.4 72.2 9.8
 
Average Small Arterial    
 NaNO2 Ctrl   
     
 #1 #2 Average  
 S S S 
Std. 
Error 
Initial  9.26 20.56 14.9 5.65
Baseline 10.85 23.34 17.1 6.245
10uM        
1 min 7.82 21.3 14.6 6.74
5 min 8.97 22.04 15.5 6.535
10 min 8.98 23.26 16.1 7.14
100uM        
1 min 11.4 21.9 16.7 5.25
5 min 8.28 19.13 13.7 5.425
10 min 8.99 19.96 14.5 5.485
1mM        
1 min 11.49 19.86 15.7 4.185
5 min 10.49 19.84 15.2 4.675
10 min 10.41 18.57 14.5 4.08
3mM        
1 min 9.53 16.66 13.1 3.565
5 min 10.28 19.93 15.1 4.825
10 min 10.58 20.2 15.4 4.81
 
Average Medium Arterial    
 NaNO2 Ctrl   
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 #1 #2 Average  
 M M M 
Std. 
Error 
Initial  223.67 205.6 214.6 9.035
Baseline 252.05 203.3 227.7 24.375
10uM        
1 min 211.33 201.73 206.5 4.8
5 min 190.94 219.57 205.3 14.315
10 min 190.06 182.69 186.4 3.685
100uM        
1 min 168.42 229.29 198.9 30.435
5 min 178.93 192.43 185.7 6.75
10 min 173.85 186.78 180.3 6.465
1mM        
1 min 176.82 201.19 189.0 12.185
5 min 153.49 215.15 184.3 30.83
10 min 138.33 202.05 170.2 31.86
3mM        
1 min 174.22 198.02 186.1 11.9
5 min 163.4 205.65 184.5 21.125
10 min 162.77 202.7 182.7 19.965
 
Average Large Arterial    
 NaNO2 Ctrl   
     
 #1 #2 Average  
 L L L 
Std. 
Error 
Initial  274.46 293.18 283.8 9.36
Baseline 270.26 285.29 277.8 7.515
10uM        
1 min 242.09 301.52 271.8 29.715
5 min 300.08 306.15 303.1 3.035
10 min 298.54 297.15 297.8 0.695
100uM        
1 min 254.55 311.47 283.0 28.46
5 min 275.66 288.62 282.1 6.48
10 min 259.3 284.24 271.8 12.47
1mM        
1 min 266.28 281.19 273.7 7.455
5 min 231.81 316.23 274.0 42.21
10 min 236.05 293.49 264.8 28.72
3mM        
1 min 214 286.88 250.4 36.44
5 min 246.58 315.5 281.0 34.46
10 min 244.9 311.19 278.0 33.145
 
NaNO2 #1 2/7/2008   
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Time Response    
     
 
Card 
# 212320   
 Wt. 348   
     
 MAP S M L 
Initial  106.3 24.88 195.44 333.63 
Baseline 102.1 24.33 159.51 250.87 
100uM 
HBOC 124.5       
1 min 140.6 18.21 177.98 262.58 
5 min 138.5 18.93 189.51 250.61 
10 min 135.4 14.91 162.45 260.86 
100uM 132.4       
1 min 131.5 16.28 167.99 181.53 
5 min 122.4 16.67 166.48 208.01 
10 min 119.3 15.28 172.35 247.53 
15 min 117.3 15.17 158.37 208.84 
25 min 118.7 16.34 163.99 239.22 
1mM 105.3       
1 min 104.3 14.77 180 241.74 
5 min 115.3 15.1 143.59 217.18 
10 min 105.3 14.72 166.75 216.73 
15 min 118.6 15.38 148 191.72 
25 min 120.3 15.25 177.41 171.03 
 
Average MAP      
HBOC 201       
Time Ctrl      
 #1 #2 Average
Std. 
Dev Average
 MAP MAP MAP MAP ∆ MAP 
Initial  80.5 91.3 85.9 5.4 85.9
Baseline 81.5 80.9 81.2 0.3 81.2
100uM 116.3 118.3 117.3 1 36.1
1 min 123.4 133.8 128.6 5.2 47.4
5 min 135.4 133.6 134.5 0.9 53.3
10 min 120.8 137.3 129.1 8.25 47.9
25 min 111.8 110.7 111.3 0.55 30.1
40 min 105.4 103.5 104.5 0.95 23.3
55 min 98.3 98.5 98.4 0.1 17.2
60 min 90.0 125.5 107.8 17.75 26.6
 
Average Small Arteriole     
HBOC 201 Time Ctrl     
      
 #1 #2 Average
Std. 
Dev Average
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 S S S S ∆ S 
Initial  27.87 13.8 20.8 7.035 20.8
Baseline 32.61 13.89 23.3 9.36 23.3
100uM          
1 min 33.48 16.46 25.0 8.51 1.7
5 min 30.86 18.36 24.6 6.25 1.4
10 min 34.38 17.39 25.9 8.495 2.6
25 min 36.38 15.48 25.9 10.45 2.7
40 min 35.34 12.46 23.9 11.44 0.7
55 min 30.87 17.83 24.4 6.52 1.1
 
Average Medium 
Arteriole    
HBOC 201 Time Ctrl    
     
 #1 #2 Average
Std. 
Dev 
 M M M M 
Initial  186.31 109.99 148.2 38.16
Baseline 203.3 102.41 152.9 50.445
100uM        
1 min 243.17 125.16 184.2 59.005
5 min 222.58 125.54 174.1 48.52
10 min 249.25 153.02 201.1 48.115
25 min 222.36 154.11 188.2 34.125
40 min 218.51 143.23 180.9 37.64
55 min 200.49 154.23 177.4 23.13
 
Average Large Arteriole    
HBOC 201 Time Ctrl    
     
 #1 #2 Average
Std. 
Dev 
 L L L L 
Initial  240.11 234.02 237.1 3.045
Baseline 266.64 189.38 228.0 38.63
100uM        
1 min 283.84 181.01 232.4 51.415
5 min 264.76 198.89 231.8 32.935
10 min 265.53 192.93 229.2 36.3
25 min 275.18 210.03 242.6 32.575
40 min 253.38 192.93 223.2 30.225
55 min 244.29 218.84 231.6 12.725
 
Average MAP         
HBOC 201 + NaNO2        
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 #1 #2 #3 #4 #5 #6 Average  
 MAP MAP MAP MAP MAP MAP MAP 
Std. 
Error 
Initial  84.2 81.5 78.3 113.3 86.4 70.1 85.6 6.000648
Baseline 84.8 80.8 81.3 112.9 90.1 80.4 88.4 5.125974
0.01uM 104.3 90.1 130.8 125.3 130.9 101.3 113.8 7.122379
1 min 110.5 129.5 124.8 158.9 142.9 120.3 131.2 7.060017
5 min 120.9 134.1 123.6 160.3 132.8 123.5 132.5 5.972865
10 min 119.5 124.5 125.4 142.7 130.1 126.7 128.2 3.231692
0.1uM 116.5 120.4 123.5 138.7 129.3 132.2 126.8 3.341424
1 min 114.3 124.8 122.7 135.3 128.1 121.5 124.5 2.863302
5 min 109.3 115.3 121.6 133.1 127.7 123.1 121.7 3.47682
10 min 104.3 115.1 120.3 133.1 132.3 120.3 120.9 4.429898
1uM 101.2 113.1 120.2 130.1 130.1 121.3 119.3 4.487514
1 min 102.3 113.1 119.5 129.1 128.3 124.1 119.4 4.193249
5 min 99.4 112.3 120.1 130.3 124.2 116.3 117.1 4.361269
10 min 92.4 110.7 118.3 127.1 118.3 109.8 112.8 4.811629
10uM 83.1 108.3 115.3 121.2 116.3 107.3 108.6 5.522585
1 min 60.1 105.1 114.2 124.3 111.3 105.4 103.4 9.1244
5 min 85.1 99.3 110.3 125.8 105.3 105.3 105.2 5.444289
10 min 84.3 96.3 105.3 124.6 103.8 98.3 102.1 5.429242
100uM 64.3 87.1 100.3 112.3 98.5 95.4 93.0 6.633974
1 min 35.1 86.3 91 107.0 78.4 88.8 81.1 9.964002
5 min 36.3 81.8 81 108.3 82.9 85.4 79.3 9.573067
10 min 26.1 78.3 82 113.1 79.0 80.3 76.5 11.45119
 
Average 
Small          
HBOC 201 + NaNO2        
         
 #1 #2 #3 #4 #5 #6 Average  
 S S S S S S S 
Std. 
Error 
Initial  23.22 32.72 32.74 28.98 22.15 14.31 25.7 2.933055
Baseline 22.56 31.98 25.74 29.43 25.46 17.23 25.4 2.11716
0.01uM                
1 min 22.43 33.85 27.05 28.69 25.95 21.99 26.7 1.790484
5 min 28.46 32.81 25.6 29.53 22.95 20.48 26.6 1.847311
10 min 28.3 30.81 27.42 31.35 23.44 21.55 27.1 1.607845
0.1uM                
1 min 27.48 34.97 26.21 29.89 24.91 22.48 27.7 1.778939
5 min 30.92 31.45 27.42 28.3 28.83 20.17 27.8 1.660473
10 min 21.42 33.84 27.32 27.43 19.02 20.08 24.9 2.324393
1uM                
1 min 25.4 37.13 24.37 31.75 20.46 21.15 26.7 2.652959
5 min 24.76 33 30.87 28.61 20.26 20.46 26.3 2.191389
10 min 24.44 34.14 28.54 31.88 24.21 21.65 27.5 1.989661
10uM                
1 min 27.73 36.46 29.62 29.3 19.93 22.64 27.6 2.372877
5 min 25.43 32.18 29.42 29.6 22.7 17.85 26.2 2.162207
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10 min 25.05 34.8 23.07 29.63 22.57 20.37 25.9 2.187257
100uM                
1 min 23.81 34.47 23.7 30.03 22.44 21.92 26.1 2.060462
5 min 24.44 26.05 25 29.26 25.2 20.11 25.0 1.20437
10 min 23.27 34.12 24.39 28.61 24.13 22.76 26.2 1.793627
 
Average Medium        
HBOC 201 + NaNO2        
         
 #1 #2 #3 #4 #5 #6 Average  
 M M M M M M M 
Std. 
Error 
Initial  259.22 167.23 208.69 252.11 226.23 182.74 216.0 15.07174
Baseline 278 233.22 292.74 260.06 196.51 219.7 246.7 14.95282
0.01uM                
1 min 260.68 212.8 271.3 246.62 214.64 241.96 241.3 9.707937
5 min 277.62 218.51 225.59 247.52 222.3 243.1 239.1 9.054271
10 min 277.47 225.62 206.28 233.01 200 254.28 232.8 11.95484
0.1uM                
1 min 276.86 209.8 200.29 212.56 238.28 233.6 228.6 11.34299
5 min 287.25 210.75 218.72 227.36 213.41 252.03 234.9 12.10736
10 min 282.94 200.08 206.31 209.83 208.47 291.37 233.2 17.16153
1uM                
1 min 277.27 243.06 219.67 218.65 220.82 239.61 236.5 9.242351
5 min 268.9 242.01 255.36 199.22 200.38 255.05 236.8 12.21169
10 min 269.88 246.2 253.1 219.02 242.01 236.54 244.5 6.927665
10uM                
1 min 243.49 271.46 244.46 211.44 231.92 228.09 238.5 8.227369
5 min 268.83 270.48 238.66 222.83 228.37 212.4 240.3 9.922046
10 min 253.16 206.44 206.44 223.92 244.31 218.3 225.4 7.957731
100uM                
1 min 169.58 261.67 160.43 246.67 242.85 246.6 221.3 18.03513
5 min 172.26 225.24 178.38 243.67 243.75 255.89 219.9 14.66413
10 min 168.26 243.05 189.79 219.72 241.33 261.5 220.6 14.48683
 
Average 
Large         
HBOC 201 + NaNO2        
         
 #1 #2 #3 #4 #5 #6 Average  
 L L L L L L L 
Std. 
Error 
Initial  272.59 262.26 238.72 309.02 290.77 240.36 269.0 11.35923
Baseline 346.67 268.75 309.12 267.39 234.06 264.53 281.8 16.23761
0.01uM                
1 min 290.08 307.74 310.5 288.84 261.57 287.34 291.0 7.177533
5 min 317.54 308.89 309.5 281.88 252.76 289.81 293.4 9.796424
10 min 334.14 304.88 293.81 293.62 250.47 282.01 293.2 11.20136
0.1uM                
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1 min 329.12 251.53 326.29 267.13 245.43 280.62 283.4 14.89935
5 min 362.29 278.75 310.89 256.75 259.74 281.05 291.6 16.20204
10 min 358.43 260.64 326.7 249.87 255.47 266.23 286.2 18.41533
1uM                
1 min 363.2 365.07 273.68 256.74 263.87 266.26 298.1 20.98845
5 min 359.4 338.99 284.41 256.75 266.78 254.38 293.5 18.33908
10 min 357.3 309.14 278.34 249.87 243.38 285.5 287.3 17.1177
10uM                
1 min 372.25 336.38 279.29 246.15 241.7 255.57 288.6 21.95413
5 min 346.72 328.78 307.17 270.07 250.07 269.55 295.4 15.54685
10 min 295.86 311.31 306.72 238.15 251.01 286.99 281.7 12.34196
100uM                
1 min 185.41 273.29 260.65 306.38 305.86 289.02 270.1 18.46154
5 min 185.25 289.5 213.22 282.56 326.05 266.91 260.6 21.263
10 min 184.09 303.5 200.68 263.18 314.22 295.8 260.2 22.66027
 
Average MAP     
HBOC 201 + NaNO2 Simultaneous   
     
 #1 #2 Average  
 MAP MAP MAP 
Std. 
Error 
Initial  104.6 87.8 96.2 8.4
Baseline 105.7 82.1 93.9 11.8
100uM (HBOC) + 
NaNO2 131.6 109.3 120.5 11.15
1 min 125.6 113.4 119.5 6.1
5 min 107.3 104.5 105.9 1.4
10 min 105.3 105.6 105.5 0.15
3 mM 95.4 81.3 88.4 7.05
1 min 92.5 81.6 87.1 5.45
5 min 98.3 80.4 89.4 8.95
10 min 105.7 82.1 93.9 11.8
 
Average MAP     
HBOC 201 + NaNO2 Simultaneous   
     
 #1 #2 Average  
 S S S 
Std. 
Error 
Initial  31.74 29.14 30.4 1.3
Baseline 33.36 28.57 31.0 2.395
HBOC + 1 mM 
NaNO2        
1 min 28.66 33.44 31.1 2.39
5 min 28.16 29.91 29.0 0.875
10 min 34.68 30.68 32.7 2
3 mM        
1 min 43.84 32.9 38.4 5.47
5 min 40.22 31.65 35.9 4.285
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10 min 42.53 33.73 38.1 4.4
 
Average Medium Arteriole    
HBOC 201 + NaNO2 Simultaneous   
     
 #1 #2 Average  
 M M M 
Std. 
Error 
Initial  222.72 231.97 227.3 4.625
Baseline 272.43 181.29 226.9 45.57
HBOC + 1mM 
NaNO2        
1 min 255.22 199.18 227.2 28.02
5 min 257.76 210.95 234.4 23.405
10 min 261.55 199.68 230.6 30.935
3 mM        
1 min 293.44 203.97 248.7 44.735
5 min 276.99 216.51 246.8 30.24
10 min 237.13 215.3 226.2 10.915
 
 
Average Large Vessels    
HBOC 201 + NaNO2 Simultaneous   
     
 #1 #2 Average  
 L L L 
Std. 
Error 
Initial  327.42 282.57 305.0 22.425
Baseline 333.36 212.91 273.1 60.225
HBOC +1mM  
NaNO2        
1 min 354.22 229.91 292.1 62.155
5 min 358.07 236.05 297.1 61.01
10 min 353.94 236.09 295.0 58.925
3 mM        
1 min 368.53 279.08 323.8 44.725
5 min 350.27 259.76 305.0 45.255
10 min 372.81 236.05 304.4 68.38
 
Average MAP         
L-NAMEAND NaNO2        
         
 #1 #2 #3 #4 #5 #6 Average  
 MAP MAP MAP MAP MAP MAP MAP 
Std. 
Error 
Initial  88.5 94.9 77.1 87.9 88.1 88.3 87.5 2.345729
Baseline 81.5 88.6 79.0 89.1 73.4 81.9 82.3 2.427722
5mg/kg 152.5 104.5 83.0 92.3 88.1 91.3 102.0 10.51867
1 min 157.7 136.5 123.5 123.8 137.3 131.3 135.0 5.145251
5 min 155.3 149.5 154.8 163.4 157.3 152.7 155.5 1.915028
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10 min 140.1 132.5 148.5 145.4 153.7 149.3 144.9 3.09197
100 uM 123.1 148.8 146.8 135.7 151.1 149.1 142.4 4.465696
1 min 119.8 142.5 142.3 131.7 142.1 145.3 137.3 3.986178
5 min 117.3 135.8 139.1 125.8 135.3 141.7 132.5 3.754375
10 min 115.1 130.5 137.4 118.3 130.8 138.5 128.4 3.966835
1 mM 103.1 115.3 129.1 110.3 128.1 131.3 119.5 4.749012
1 min 105.1 110.2 121.8 101.3 120.2 125.7 114.1 4.045965
5 min 100.9 109.1 108.4 95.1 107.9 118.3 106.6 3.229078
10 min 98.9 102.3 98.7 92.1 104.8 101.4 99.7 1.780075
3 mM 98.7 98.3 95.4 89.1 100.8 100.7 97.2 1.802899
1 min 89.3 95.2 88.5 88.7 88.3 91.9 90.3 1.116069
5 min 80.5 92.3 81.3 84.3 84.0 80.3 83.8 1.843261
10 min 80.1 79.3 78.5 85.1 78.8 81.2 80.5 1.002331
 
Average Small Vessel Diameter       
L-NAME  + NaNO2        
         
 #1 #2 #3 #4 #5 #6 Average  
 S S S S S S S 
Std. 
Error 
Initial  11.27 28.66 36.93 51.38 26.58 30.38 30.9 5.369891
Baseline 12.22 30.89 40.03 44.16 26.01 32.38 30.9 4.597882
5mg/kg           35.31    
1 min 13.17 31.46 36.09 47.86 29.96 30.16 31.5 4.578429
5 min 10.08 33.76 37.03 46.02 30.93 27.29 30.9 4.901912
10 min 8.75 33 33.08 41.42 30.76 30.76 29.6 4.475085
100 uM                
1 min 11.5 32.1 33.43 43.87 27.64 29.27 29.6 4.305442
5 min 11.72 29.7 34.92 39.29 29.88 27.42 28.8 3.843171
10 min 14.08 32.97 34.25 38.26 23.52 30.83 29.0 3.582622
1 mM                
1 min 12.7 28.54 32.64 46.55 27.21 26.27 29.0 4.463964
5 min 15.38 30.47 32.06 36.59 22.17 25.51 27.0 3.110094
10 min 13.98 31.18 31.5 35.73 23.89 26.99 27.2 3.124415
3 mM                
1 min 12.45 31.06 30.27 41.11 25.12 27.58 27.9 3.815031
5 min 11.5 28.58 25.67 40.17 24.12 21.45 25.2 3.823834
10 min 12.84 28.46 28.77 37.02 21.72 27.05 26.0 3.30539
 
Average Medium Vessel Diameter       
L-NAME  + NaNO2        
         
 #1 #2 #3 #4 #5 #6 Average  
 M M M M M M M 
Std. 
Error 
Initial  175.13 301.52 133.65 213.95 160.47 160.2 190.8 24.60541
Baseline 153.4 258.95 150.04 231.89 182.08 196.13 195.4 17.67258
5mg/kg                
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1 min 208.2 260.64 133.77 242.94 207.11 206.98 209.9 17.77747
5 min 202.27 231.54 137.6 207.75 229.29 169.89 196.4 14.87735
10 min 190.08 289.68 136.29 157.36 239.3 241.89 209.1 23.67871
100 uM                
1 min 165.62 299.59 141.87 177.26 214.19 243.86 207.1 23.67976
5 min 172.35 283.84 127.4 174.76 223.15 221.98 200.6 22.14988
10 min 183.6 264.7 119.63 177.48 222.53 242.99 201.8 21.41446
1 mM                
1 min 253.7 297.7 135.84 233.94 230.36 245.47 232.8 21.76988
5 min 262.63 293.7 126.25 225.94 252.33 216.52 229.6 23.51038
10 min 268.84 279.82 118.74 175.62 207.58 180.07 205.1 24.90357
3 mM                
1 min 201.41 254.5 119.85 221.14 224.87 159.05 196.8 20.06429
5 min 216.83 281.51 116.24 228.93 234.71 226.1 217.4 22.25012
10 min 239.26 270.25 123.84 183.72 237.13 223.55 213.0 21.18767
 
Average Large Vessel Diameter       
L-NAME  + NaNO2        
         
 #1 #2 #3 #4 #5 #6 Average  
 L L L L L L L 
Std. 
Error 
Initial  331.88 325.43 281.43 323.3 248.06 296.66 301.1 13.23135
Baseline 290.56 315.65 298.07 315.3 282.64 300.9 300.5 5.392613
5mg/kg                
1 min 304.11 351.98 262.29 308.67 313.21 305.88 307.7 11.64801
5 min 380.39 344.56 286.14 270.58 349.55 311.96 323.9 17.01693
10 min 316 336.05 283.6 263.5 333.06 323.88 309.3 11.96618
100 uM                
1 min 367.96 353.6 246.86 267.19 328.76 304.87 311.5 19.53092
5 min 365.41 363.92 251 293.88 312.76 318.6 317.6 17.75196
10 min 373 341.27 250.31 270.59 313 303.59 308.6 18.34996
1 mM                
1 min 341.24 348.89 285.6 244.14 325.52 316.83 310.4 16.02911
5 min 332.49 374.4 294.8 282.56 289.77 320.03 315.7 14.08755
10 min 312.11 340.21 293.23 252.56 266.33 323.5 298.0 13.81009
3 mM                
1 min 345.33 348.32 295.67 253.81 305.88 259.83 301.5 16.50967
5 min 354.36 350.49 284.41 256.67 306.68 384.08 322.8 19.68488
10 min 353.99 331.04 298.18 276.47 312.86 318.48 315.2 10.8957
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Average Large Vessel Diameter       
L-NAME  + NaNO2        
         
 #1 #2 #3 #4 #5 #6 Average  
 L L L L L L L 
Std. 
Error 
Initial  331.88 325.43 281.43 323.3 248.06 296.66 301.1 13.23135
Baseline 290.56 315.65 298.07 315.3 282.64 300.9 300.5 5.392613
5mg/kg                
1 min 304.11 351.98 262.29 308.67 313.21 305.88 307.7 11.64801
5 min 380.39 344.56 286.14 270.58 349.55 311.96 323.9 17.01693
10 min 316 336.05 283.6 263.5 333.06 323.88 309.3 11.96618
100 uM                
1 min 367.96 353.6 246.86 267.19 328.76 304.87 311.5 19.53092
5 min 365.41 363.92 251 293.88 312.76 318.6 317.6 17.75196
10 min 373 341.27 250.31 270.59 313 303.59 308.6 18.34996
1 mM                
1 min 341.24 348.89 285.6 244.14 325.52 316.83 310.4 16.02911
5 min 332.49 374.4 294.8 282.56 289.77 320.03 315.7 14.08755
10 min 312.11 340.21 293.23 252.56 266.33 323.5 298.0 13.81009
3 mM                
1 min 345.33 348.32 295.67 253.81 305.88 259.83 301.5 16.50967
5 min 354.36 350.49 284.41 256.67 306.68 384.08 322.8 19.68488
10 min 353.99 331.04 298.18 276.47 312.86 318.48 315.2 10.8957
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